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More than a third of the world’s population is affected by latent tuberculosis 
(LTBI). Since the 1800s the tuberculin skin test (TST) has been the only 
available test for LTBI. Recently, interferon-gamma release assays (IGRAs) 
have been developed which are based upon the responses of peripheral 
blood effector cells to M.tb-specific antigens [early secretory antigenic target -
6 (ESAT-6) and culture filtrate protein (CFP10)]. Discordance between the 
TST and IGRAs has been well documented but remains largely unexplained. 
By contrast, active tuberculosis (TB) results in approximately 10 million cases 
per year and approximately 2 million deaths. However, control efforts are 
hampered by suboptimal diagnostic tools and techniques 
 
Methods: 
Quantitative PCR of tissue from TST skin biopsies was used to investigate 
the immunopathogenesis of TST-positive, IGRA-negative discordance in the 
setting of LTBI. In smear negative and sputum scarce individuals, antigen-
specific responses in cells from induced sputum were evaluated in a 
standardized ELISPOT assay incorporating ESAT-6 and CFP10. Additionally, 
LAM, a heat stable lipopolysaccharide antigenic marker of the genus 
Mycobacterium, was evaluated as a diagnostic marker in induced sputum. 
 
Results/ Conclusions: 
It was found that regulatory T cells (Tregs) and cytokines such as IL-4 were 
expressed at a higher level in TST-positive, IGRA-negative compared to 
TST-positive, IGRA-positive subjects.  In induced sputum, whilst the 
ELISPOT assay showed that rapid immunodiagnosis is indeed possible, its 
clinical feasibility is limited as only 11% of the results were evaluable. Finally, 
the non-cellular fraction of induced sputum was evaluated using a 
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was feasible when using induced sputum, the sensitivity and specificity of the 
















In 2003 the World Health Organisation declared tuberculosis (TB) a global health 
emergency (World Health Organisation, 2009). TB remains a major health 
problem worldwide, with one third of the world’s population thought to be infected 
with the disease. The most recent WHO report estimates that 13.7 million 
individuals had active TB in 2007 (206 per 100 000 population), and 9.27 million 
people (139 per 100 000) developed TB in that year alone (WHO, 2009).  
 
Figure 1.1 Estimated number of new TB cases per 100 000 population. (World 











An estimated 15% of all incident TB cases were HIV-positive; 79% of these were 
in the African region and 11% were in the South-East Asia region. 
 
Most of the TB cases recorded in 2007 were in Asia (55%) and Africa (31%). The 
five countries that ranked first to fifth in terms of total number of cases in 2007 
were India (2 million), China (1.3 million),  Indonesia (0.5 million), Nigeria (0.46 
million) and South Africa (0.46 million) (World Health Organisation, 2009). The 
extremely high prevalence of TB, especially in sub-Saharan Africa, (Corbett et 
al., 2006) could be attributed to several factors. These include the HIV pandemic, 
poverty, lack of an effective vaccine, non-availability of a healthcare infrastructure 
in many poor areas and importantly, a lack of a rapid and accurate TB-specific 
diagnostic method. 
 
1.2 HISTORY & PATHOGENESIS 
The causative agent for tuberculosis was identified by Robert Koch in 1881 
although evidence of TB dates back, according to one report, to 1000-400 BC 
(Zimmerman, 1979). Koch identified the bacillus as a slender, straight or slightly 
curved organism which is non-motile and does not form spores (Figure 1.2).  
 
 











The causative agent of tuberculosis is Mycobacterium tuberculosis (M.tb) – a 
bacillus with specific and typical pathogenetic traits in the human host. It is 
spread primarily by droplet inhalation of only 1-10 bacteria, usually via a cough of 
an infected tuberculous patient (Sundaramurthy and Pieters, 2007). Most people 
exposed to M.tb will not become infected and of those infected, a further 90% will 
remain asymptomatic as the mycobacteria can remain dormant as latent TB 
infection (LTBI) (Russell, 2007). LTBI describes a clinically asymptomatic state 
when the host shows no signs of active disease yet has viable, non-replicating 
M.tb organisms within tissues (Dheda et al., 2010). 
 
Once infection has occurred alveolar macrophages and dendritic cells (DCs) in 
the distal airways are the first to be exposed to the droplets containing the M.tb 
pathogens (Meya and McAdam, 2007). Phagocytosis is facilitated by Toll-like 
receptors (TLR), macrophage mannose receptors and complement receptor 3 
(Ernst, 1998). Although the bacilli are engulfed, many of these virulent bacteria 
resist phagocytosis and intracellular killing by interfering with host trafficking 
pathways. They inhibit the maturation f the bacillus-containing phagosome and 
fusion with the lysosome (Sturgill-Koszycki et al., 1996). In addition, the bacilli 
can modulate the membrane proton-pump inhibitor, thereby preventing 
acidification of the phagolysosome. The bacilli have molecules in their cell walls 
which may be cytotoxic, such as LAM, which inhibit the cell’s response to 
interferon-γ (IFN-γ), and the ability to present antigen (Rook and Hernandez-
Pando, 1996). Thus, mycobacteria manage to create a safe environment within 
the macrophage where they can survive and even replicate (Houben et al., 
2006). 
 
In the early stages of infection, only the lung compartments are involved so no 
naïve CD4+ T cells are exposed to foreign antigens. The bacterial population are 
hereby allowed time to grow and resist the host adaptive immune response (Wolf 











infection as M.tb-infected macrophages are lysed and bacilli are released. Thus, 
there are no associated signs or symptoms of disease in the early stages of 
infection.  
 
The adaptive immune response is primarily initiated upon stimulation in the 
lymph nodes (Salgame, 2005). Here, infected DCs upregulate major 
histocompatibility (MHC) Class II and co-stimulatory molecules and present 
captured M.tb antigens to naïve T cells (Alaniz et al., 2004). Approximately 2-6 
weeks after initial infection (Edwards and Kirkpatrick, 1986), activated T-cells 
migrate to inflammatory sites in the lungs to initiate an ongoing interaction 
between T-lymphocytes and macrophages in the form of a cellular mass called a 
granuloma, or tubercle, hence the name of the disease (Russell, 2007). 
 
The granuloma consists of a caseating centre of degenerating infected 
macrophages and multi-nucleated foamy giant cells (Langhans), surrounded by 
peripheral mononuclear cells. During this phase of disease, the mycobacteria are 
contained. There are still no signs of disease and the individual is not infectious. 
The tubercle may become surrounded by fibroblasts and then calcify, forming the 
typical x-ray picture seen in TB patients. Alternatively, a lowering in immune 
status, e.g. HIV, or malnutrition, may result in the bacilli growing exponentially 
thereby leaving dead and dying macrophages to form the characteristic caseous, 
necrotic intragranulomatous centre. The bacilli continue to increase in number, 
causing further necrosis which finally results in bronchial erosion and drainage of 
the liquefied material. The individual may now expectorate infectious sputum 
which can result in perpetuating disease (Cardona, 2010). 
 
Extrapulmonary TB may occur early in infection when mycobacteria spread 
distally either indirectly via the lymphatic system or through direct erosion into 











extrapulmonary sites may include the bones, pleura, genito-urinary system, 
meninges, peritoneum and skin (Raja, 2004). Persistence of viable 
extrapulmonary tubercle bacilli may result in secondary lung lesions causing 
reactivation of clinical disease years or even decades later. Primary disease is 
typified by a single granulomatous lesion in the middle or lower lobes with 
enlarged draining lymph nodes, while endogenous reactivation is often 
recognised by a single or multiple cavitations in the apical lung area with multiple 
secondary tubercles (Baron, 1996). 
 
1.3 HOST IMMUNE RESPONSE 
 
TB causes a large number of deaths, more than from any single infectious 
disease. Co-infection with HIV, especially in sub-Saharan Africa, causes further 
complications, morbidity and mortality. The host immune response can be 
subdivided into two interactive categories: 
 
1.3.1 Innate Immune Response 
Cells of the innate host immune response act as the initial, non-specific 
protection against invading pathogens. Alveolar macrophages perform a variety 
of key functions in the host response. These include: 
1. phagosome-lysosome fusion with M.tb after surface-molecule-binding,  
2. inhibition of mycobacterial growth and killing through free radical based or 
cytokine-mediated mechanisms,  
3. recruitment of specific immune cells for local inflammation, and 












Macrophages interact with other effector cells via chemokines and cytokines, 
which serve to attract and activate inflammatory cells such as lymphocytes. It is 
these contact mechanisms between the host and M. tuberculosis which may 
confer either host or bacillus protection.  
 
Cell surface receptor molecules, such as mannose receptors, play an important 
role e.g. mannose receptor and mycobacterial binding appears to be mediated by 
the mycobacterial surface glycoprotein lipoarabinomannan (LAM). Bacilli utilise 
LAM to resist phago-lysosomal formation via mycobacterial sulphatides to 
produce ammonia.  This continual macrophage necrosis leads to bacillary 
entrance into the extracellular milieu where the cellular immune response is 
evoked (Kaufmann and McMichael, 2005). Neutrophils also play a role in the 
innate immune response and are responsible for the recruitment of inflammatory 
cells for a local response. DCs transport mycobacterial antigen into the lymphoid 
tissue where the adaptive immune response can be initiated. Natural killer (NK) 
cells, natural killer T-cells (NKT) cells, and γδ cells also play a role defending the 
host against invading pathogens. Innate immunity may explain the likely 
clearance of the organism with lack of a tuberculin skin test (TST) or interferon-
gamma release assay (IGRA) reaction in a large population of exposed 














Figure 1.3 The spectrum of Mycobacterium tuberculosis infection and the life 
cycle of M. tuberculosis. (Dheda et al., 2010) 
 
1.3.2 Adaptive Immune Response 
Adaptive immunity involves all immune responses evoked for specific antigens, 
and includes the development of immunological memory. CD4+ T-cells, CD8+ T-











the initiation and control of the adaptive immune response. The CD4+ T cells can 
be divided into T helper-1(Th1), T helper-2 (Th2), T helper-17 (Th17) and 
regulatory T cells (Tregs) (Table 1.1).  
 
T-helper cell type Effector Cytokines Function 
Th1 IFNγ, TNF-α, IL-2 
Maturation and activation of 
granulocytes; pro-
inflammatory 
Th2 IL-4, IL-5, IL-9, IL-10, IL-4δ2 
Promotion of antibody 
production by B cells; 
suppression of Th1 
Th17 IL-17 
Recruitment of neutrophils to 
site of inflammation; 
suppression of Th1 and Th2 
Treg TGF-β, IL-10 
Modulation of Th1, Th2, 
Th17 
 
Table 1.1 Characteristics of the 4 main types of T helper cell types 
  
M.tb evokes a classical Th1-type cellular immune response in the host. Indeed, it 
is this response that is believed to be primarily responsible for much of the 
pathology associated with clinical TB.  
 
During infection, MHC Class II molecules present large peptides from M.tb 
residing within the macrophage vacuoles to the CD4+ T-cells, resulting in their 
activation. Interleukin-12 is induced following phagocytosis of M.tb bacilli by DCs 
and macrophages, which polarizes cells to a Th1-type immune response (Ladel 











(CMI) response and in the control of TB infection. Their primary role is the 
production of IFN-γ, and possibly other cytokines, involved in macrophage 
activation, and enhanced mycobacteriostatic or mycobacteriocidal capabilities. 
Cytokines, such as IFN-γ, decrease phagocytic receptor expression resulting in 
diminished mycobacterial adhesion (Barnes, 1994). IFN-γ is a key cytokine in the 
control of M.tb infection and is produced by CD4+ T cells, CD8+ T cells and NK 
cells. Tregs are simultaneously activated and, although their role has not been 
definitively elucidated, they have been reported to be involved in 
immunosuppression of the effector cells (Askenasy et al., 2008). 
 
Studies in murine models confirm that activated T cells migrate to the site of 
infection where they form typical tuberculous granulomas. Here both CD4+ and 
CD8+ T cells attempt to contain the infection within the granuloma and prevent 
disease reactivation. CD8+ T cells attack infected macrophages causing lysis and 
release of bacilli from their protected environment. They are then exposed to 
activated macrophages for renewed uptake and killing. CD8+ T-cells also play a 
significant role as they produce IFN-γ and IL-4. Thus, they may play a role in 
regulating the immune system balance between Th1- and Th2-type cells in the 
lungs of patients with pulmonary TB (PTB).  
 
The manner by which mycobacterial proteins gain access to MHC Class I for 
presentation to the CD8+ T cells is still poorly understood. It has been found that 
slow regression of disease while receiving therapy was associated with an 
increase in CD8+ T cells in broncho-alveolar lavage (BAL) fluid (Yu et al., 1995). 
In addition, killing of intracellular bacteria was dependent on the cytolytic 
mediators perforin and granulysin (Stenger et al., 1998). Some CD8+ T cells 
have an alternative, yet critical role in detecting infected cells where the pathogen 
is in the cytoplasm. CD1 molecules transport lipid antigens via the endoplasm for 












After exposure to M.tb, 30-50% of all individuals show no immunodiagnostic 
signs of infection (tuberculin skin test reactivity). Of the remainder, who probably 
develop LTBI, approximately 5% develop active TB within the next 2-5 years of 
initial infection. The remaining 95% are not likely to develop disease unless they 
develop an immuno-compromised state such as HIV, diabetes, malnutrition 
(Dheda et al., 2010). Concurrent symptoms of active TB disease include a 
prolonged cough, at first non-productive then mucoid and purulent, with low 
grade remittent fever, night sweats, chills, weight loss, anorexia, and fatigue, 
chest pain and haemoptysis later in disease (Kumar, 2007). 
Timeous and accurate diagnosis of TB depends upon clinical recognition of 
typical symptoms together with a medical history. Ideally this diagnosis should be 
confirmed microbiologically. Other modalities may also facilitate the diagnosis 
such as radiology, immunological and molecular-biological assays or where 
available, histology (Lange and Mori, 2010).  
 
1.4.1 Smear & culture 
In order to confirm diagnosis of M.tb disease, culture of acid fast bacilli (AFB) in 
sputum is the “gold standard” test. A drawback of microbiological smear is the 
number of false negati e results, most likely due to the need for a minimum of    
5 000 bacilli/ml of sputum (Teixeira et al., 2007). The preferred method of 
staining for M.tb is auramine-rhodamine for fluorescence microscopy, which is 
more sensitive than conventional Ziehl-Neelsen staining for light microscopy 
(Steingart et al., 2006).  Culture of M.tb organisms from a specimen [sputum, 
pus, cerebro-spinal fluid (CSF), BAL, etc.] is the most common way to make a 
definitive diagnosis. However, results may take four to eight weeks, and 












Culture is far more sensitive than smear requiring only 10-100 viable bacilli per 
ml of sputum (Colebunders and Bastian, 2000). Indeed, while smear is 
inexpensive, rapid and relatively simple, making it the preferred diagnostic 
technique for low-income high TB-burden areas, its low sensitivity remains a 
serious diagnostic limitation.  It has been shown to have a sensitivity of 20-80% 
(Steingart et al., 2007). Smear negative TB occurs more frequently in HIV-
positive than in HIV-negative individuals (Johnson et al., 1998). Only 44% of all 
new cases are identified by the presence of AFB on sputum smears (WHO, 
2009). 
 
 1.4.2 Immunological tests 
There are several other techniques currently employed to aid the diagnosis of TB 
(latent infection or active disease). These include th  tuberculin skin test (TST), 
interferon-gamma release assays [(IGRAs) including T-SPOT®.TB, 
QuantiFERON® TB Gold in Tube], LAM ELISA, and nucleic acid amplification 
tests (NAATs). A short summary of each of these follows. 
 
1.4.2.1   Tuberculin Skin Test (TST) 
The TST remains the standard for immunodiagnosis of latent TB since the 
beginning of the 20th century. Until recently, it was the only means of diagnosis in 
LTBI. A meta-analysis by Pai et al. in 2008 showed the overall sensitivity of the 
TST to be approximately 77% (Pai et al., 2008). The TST involves an intradermal 
injection of an extract of sterile supernatant of M.tb-cultured filtrate called purified 
protein derivative (PPD) (Sarrazin et al., 2009). In individuals previously exposed 
to TB, 48-72 hours after PPD administration a palpable raised induration of the 
skin develops. The extent of induration is measured and a cut off of 5-15 mm 
determined by patient risk-factors such as immune status, HIV-status, high-risk 












The TST reaction is based upon a delayed type hypersensitivity response to 
PPD, a crude mixture of approximately 200 M.tb antigens (Lee and Holzman, 
2002). As this mixture contains antigens common to Mycobacterium bovis and 
other non-tuberculous mycobacteria (NTM), it’s specificity in Bacille Calmette-
Guérin (BCG)-vaccinated populations may be unreliable. The “boosting” 
phenomenon results in complicated interpretation of serial TST testing (van Zyl-
Smit et al., 2009). Positivity of the TST may also be associated with age, foreign 
birth immigrants in low burden, first world settings) and increased time as a 
healthcare worker – all indicators of possible remote exposure to M.tb (Alvarez-
Leon et al., 2009). In immunocompromised individuals such as sufferers of 
HIV/AIDS, advanced TB, malnutrition, poverty or malignancy, sensitivity may be 
low. (Andersen et al., 2000). Additionally, Lawn et al. reported that patients with a 
low CD4+ cell count have a high rate of false negative results (Lawn et al., 2009).   
 
It is not an expensive test requiring a specialised laboratory, and can be 
performed in the field. Specific training is required to apply the test accurately but 
no other medical expertise is required. Thus, it is ideal for resource-poor settings. 
However, one of the biggest drawbacks of the TST is that it is unable to 
distinguish between active TB and LTBI (Lange et al., 2009).  
 
  1.4.2.2   Interferon gamma release assay (IGRA) 
A new in vitro blood test which measures the Th1-type immune response has 
been developed namely the interferon gamma release assay (IGRA). The UK 
National Institute of Health and Clinical Excellence (NICE) now recommends the 
use of IGRAs in i) individuals who are at risk of LTBI and have tested positive by 
TST, and ii) individuals in whom the TST would be unreliable e.g. 
immunosuppressive conditions, who would often give a false negative result. In 
contrast, the guidelines of the United States of America recommend the use of 












There are currently two types of commercially available IGRAs, namely i) 
QuantiFERON®-TB Gold and Gold-in-Tube (QFT and QFT-IT respectively) 
(Cellestis Ltd, Carnegie, Australia) and ii) T-SPOT®.TB (Oxford Immunotec, 
Oxford, United Kingdom). IGRAs have been shown to be highly sensitive and 
specific tests for the diagnosis of latent M.tb infection (LTBI) (Dheda et al., 2005; 
Pai et al., 2008). 
 
Both types of assays determine the ex vivo release of interferon-γ (IFN-γ) from 
pre-sensitized host effector (memory) T-cells after overnight stimulation with 
M.tb-specific antigens. These antigens are early secreted antigenic target 6kDa 
(ESAT-6), and culture filtrate protein 10 (CFP-10) and additionally TB 7.7 in the 
QFT-GIT assay. They are encoded on the region of difference (RD-1) in the M.tb 
genome, a region associated with virulence and attenuation of the BCG vaccine. 
This domain is absent from BCG substrains and many non-tuberculous 
mycobacteria (NTM) except M. marinarum, M.szulgai and M.kansasii (Arend et 
al., 2000; Dheda et al., 2009; Lalvani et al., 2001). There are, however, 
homologues of these proteins in the genome of M.leprae (Gey van Pittius et al., 
2002).  
 
IGRAs show less cross-reactivity with the BCG vaccine strain (Dheda et al., 
2005; Pai et al., 2007) and with most NTM (Andersen et al., 2000), thereby 
showing improved specificity than the TST. This could be explained by the fact 
that PPD stimulation in the TST measures a variety of protein antigens, whereas 
IGRAs measure IFN-γ responses to only two or three antigenic stimuli encoded 
on the RD-1 of M.tb. The approximate specificity of the IGRAs is 95% (Lewis et 
al., 2003). A further advantage of the IGRAs is that a single visit by the patient 
may be adequate in appropriate circumstances. In addition, should serial testing 
be necessary, such as in immuno-compromised patients or health care workers, 
this is possible as there is no induction of the “boosting” phenomenon (van Zyl-











IGRAs, unlike the TST, have an internal positive control to indicate whether test 
results are indeterminate or evaluable (Dheda et al., 2005). The validation of 
IGRAs to detect LTBI suffers from the lack of a gold standard, so active TB 
disease has often been used as a proxy marker for LTBI. Studies of IGRA 
responses in asymptomatic first-world subjects at low risk of LTBI were 
performed to determine specificity (Dheda et al., 2005; Lalvani and Pareek). 
IGRAs may be more reactive than TSTs in certain settings; they may detect up to 
70-80% of individuals with LTBI (Mori, 2009; Pai et al., 2004). 
 
The use of IGRAs to diagnose LTBI is not commonly used in the developing 
world. Although a substantial proportion of the population has LTBI, the lifetime 
chance of developing active TB may be as low as 5% (Falk and Fuchs, 1978). 
Yet, in the developing world IGRAs probably have especially great importance as 
compulsory BCG vaccine administered at birth may increase the risk of a false-
positive TST result. The high annual risk of TB transmission results in healthcare 
facilities being overly stretched to handle the high numbers of active TB cases, 
especially in children. In addition, technical problems such as the requirement for 
cold rooms to store reagents and incubators to process samples, highly qualified 
trained laboratory personnel in equipped laboratories, and the high cost pose 
even greater problems. Consequently, the use of IGRAs in the developing world 
would probably be restricted to the following situations: epidemiologic 
surveillance, children with TB, malnourished TB patients and HIV-TB co-infection 
(Dheda et al., 2009). 
 
Sensitivity of the IGRAs for diagnosis of active TB is suboptimal, with false-
negative results in both HIV-negative and HIV-positive individuals (Menzies et al., 
2007). This is explained by the fact that IGRAs rely on CD4+ cells and their 
performance will be influenced by conditions with dysfunctional CD4+ cells. In 











IL4, IL9 and IL10, and the action of Tregs can result in false negative IGRAs. 
These will be discussed in Chapter 3. 
  T-SPOT®.TB  
The T-SPOT®.TB test measures spots formed by purified IFN-γ-producing T cells 
in an enzyme-linked immunospot (ELISPOT) technique [spot forming cells/well 
(SFCs/well)].   
 
Figure 1.4  T-SPOT®.TB test kit 
For the T-SPOT®.TB assay, peripheral blood mononuclear cells (PBMCs) are 
incubated with ESAT-6, CFP-10 and PHA in a 96-well microtiter ELISPOT plate 
for 16-20 hours. If the patient is infected with M.tb, the T-cells may recognise the 
antigens and secrete IFN-γ which is captured by antibody in the bottom of each 
well. The cytokine-bound antibodies are detected and represented by spots in 
the well, where each spot corresponds to one reactive T-cell. These SFCs are 
counted to indicate the frequency of M.tb-specific T cells (Lalvani, 2007). A 
negative control well may contain up to 5 spots whilst a positive result is defined 
as ≥6 spots in either ESAT -6 or CFP-10 wells after subtracting the number of 
spots in the negative control well. For > 6spots in the negative control well:  
ESAT-6 or CFP-10 should have at least twice the number of spots as found in 
the negative control well to define a positive result. An indeterminate result 
defines a negative control well showing > 10 spots, or positive control well < 20 











4-8 spots inclusive wherein samples should be cautiously interpreted depending 
on clinical characteristics (van Zyl-Smit et al., 2009). 
 QuantiFERON®-TB Gold and QuantiFERON®-TB Gold-in-Tube  
The QuantiFERON (QFT) contains an extra M.tb-specific antigen, TB7.7 in 
vacutainer tubes pre-coated with peptides, thereby ensuring immediate exposure 
to the specimen of whole blood.  
 
Figure 1.5  QuantiFERON ®-TB Gold test kit 
After overnight exposure to M.tb antigens, the QFT assay uses an enzyme-linked 
immunosorbent assay (ELISA) technique to measure an absolute quantity of 
IFN-γ (IU/ml) in the supernatants of wh le blood.  
 
The sensitivity and specificity of the T-SPOT®.TB and QFT were examined in an 
in-depth analysis by the Centres for Disease Control and Prevention, updated 
guidelines for using IGRAs (Mazurek et al., 2010). The pooled results of the 
















Table 1.2 Pooled sensitivity and specificity rates of the immunological tests for 
TB infection 
TB test Sensitivity Specificity 
TST 89% 86% 
T-SPOT 91% 88% 
QFT-GIT 81% 99% 
 
Lee et al. found that the sensitivity in QFT ranges from 74-83% (Lee et al., 2006).  
Ferrara et al. evaluated this assay in a hospital setting and found the specificity 
to be 92.5% (95% CI 86-99%) (Ferrara et al., 2005). Pai et al. conducted a meta-
analysis of studies discussing sensitivity and specificity of IGRAs in various 
populations and specific influential factors (Pai et al., 2004). 
 
1.4.2.3  Discordance between the TST and IGRA 
 
While both the TST and IGRA may be useful diagnostic tests, a meta-analysis of 
17 studies by Pai et al.. of 17 studies showed that there is only a 60-80% 
agreement between the two tests and kappa (k) statistics were highly 
inconsistent ranging from 0.03 to 0.87. (Pai et al., 2004). Similarly, Menzies et al. 
reported a discordance of 29% between the TST and QFT (Menzies et al., 2007) 
and Soborg et al.. reported a kappa value of 0.2 due to discordant positive TST 
and QFT tests (Soborg et al., 2009). Ponce de Leon et al. reported that 
discordance is also evident in patients with inflammatory disease (Ponce de Leon 













In determining whether the TST or IGRA test reading is diagnostic, the test cut-
off is pivotal. The manufacturer’s guidelines of the commercial IGRAs are pre-
determined. Van Zyl-Smit et al. have recently described a “borderline zone” 
where within-person variability may be seen (van Zyl-Smit et al., 2009). The TST 
cut-off is determined by specific host conditions. A cut-off of ≥5mm is used in 
immunosuppressed individuals such as HIV/AIDS or patients receiving 
immunosuppressive treatment. For high risk individuals such as prison workers, 
nurses, employees in homeless shelters, hypodermic drug users or in people 
arriving less than 5 years previously from a high burden area, a cut-off ≥ 10mm is 
used. In persons with no known risk for TB infection, an induration cut-off of ≥ 
15mm is used (Duke, 2001). 
 
A false positive TST result may result from cross-reactivity with NTM as well as 
previous BCG vaccination (Lee and Holzman, 2002). BCG uses a mixture of 
approx 200 non-specific antigens, some of which are in common with NTM as 
well as Mycobacterium bovis BCG, while IGRAs use only a few M.tuberculosis-
specific antigens (Nahid et al., 2006; Pai et al., 2004).  Additionally, recent 
studies are suggesting a “boosting” phenomenon whereby the body experiences 
a “vaccination” type effect which may affect any subsequent tests readouts 
(Mawa et al., 2004; van Zyl-Smit et al., 2009). So too, the reading of the TST 
may be somewhat variable when interpreting the induration width. In active TB 
the TST may be false negative in 10-25% of cases (Nash and Douglass, 1980). 
The latter result occurs from anergy or a similar immunocompromised condition 
as the TST is a delayed type hypersensitivity reaction.  
 
The IGRA and TST do not measure the same components of the cellular immune 
response. Central memory T-cells persist long after an infection has been 
cleared, so may only produce IFN-γ during the longer incubation period 
associated with the TST, thus showing TST positivity but false IGRA negativity 











TST response may have little influence on the antigen specific T cells 
responsible for IGRA readings (Orme et al., 1991).  
 
1.4.3 LAM detection 
An alternative TB-detection method is based upon direct ELISA detection of 
LAM, a 17.5kDa heat-stable lipopolysaccharide antigenic marker of the genus 
Mycobacterium. LAM is a major and structurally vital glycolipid component of the 
mycobacterial cell wall, accounting for up to 15% of the total bacterial weight 
(Hunter et al., 1986). The mycobacterial envelope consists of the plasma 
membrane, the wall and the capsule; it is this membrane to which LAM and it’s 
precursors lipomannan (LM) and phosphatidylinositol mannosides attach (Besra 
et al., 1997). The antigenic glycolipid permeates beyond the capsule (Besra and 
Brennan, 1997; Nigou et al., 2003). The wall resembles a gram-positive wall but 
has lipid mycolate esters probably arranged to form a permeability barrier to 
















Figure 1.6 Cross-section of the mycobacterial envelope showing the position of 
LAM 
 
There are 3 types of LAM structure according to the mycobacterial species: 
mannose-capped LAM (ManLAM), phospho-myo-inositol-capped LAM (PILAM) 
and non-capped LAM (AraLAM). The capping-type is an extremely important 
determinant in the host immune response. ManLAM, which is specific to 
metabolically active, slow growing, or degrading Mycobacterium tuberculosis 
(Chan et al., 1991), has been shown to have a powerful anti-inflammatory effect 
and functions as a key virulence factor. Thus, LAM is a crucial factor in 
determining the outcome of infection (Briken et al., 2004). 
Cell surface receptor molecules such as mannose receptors (MRs) are 
expressed on macrophages and monocytes and mediate binding of 
M.tuberculosis via the latter’s surface glycoprotein, LAM. It is this coupling in 
addition to apoptosis, and phagosome maturation which LAM inhibits. LAM 











macrophages and IL-12 secretion by dendritic cells. Such mechanisms allow 
mycobacterial survival and dissemination to other parts of the body. Results from 
in vitro assays have shown that LAM mediates its biological activity via Toll-like 
receptor 2 (Briken et al., 2004).  
 
Being independent of the host immunological system, these assays, such as the 
LAM antigen-capture ELISA assay, are especially beneficial in patients with 
compromised immunological systems e.g. HIV, malnutrition, cancer. TB-HIV co-
infection is particularly prevalent in poverty stricken areas making this type of 
assay more accurate.  
 
1.4.4 NAATs and culture techniques 
More recently, newer diagnostic technologies with higher sensitivity and 
specificity are emerging. However, expertise and costly equipment make them 
somewhat prohibitive for poor-resource areas. They include M.tb-specific nucleic 
acid amplification tests (NAATs), biochemical tests used to detect mycobacteria. 
They were developed in order to shorten the time needed to obtain a diagnostic 
test result. NAATs include any test that directly detects bacterial genetic material 
such as PCR and DNA probes. 
 
Further diagnostic options include colorimetric redox indicator methods (Martin et 
al., 2008), and BACTEC460 and Mycobacterial Growth Indicator Tube (MGIT) 
culture systems. Studies have shown that liquid cultures are more rapid and 
sensitive than solid medium cultures (Cruciani et al., 2004). Liquid cultures detect 
bacterial growth in novel and unique ways such as radioactivity and oxygen 













 1.4.5 Sample acquisition 
Research into any pathological mechanisms is dependent upon the sample 
quality. Sputum is the most commonly used sample for TB diagnosis. Apart from 
expectoration, gastric washings in children, bronchoscopy, laryngeal swab, or 
even fine needle aspiration or tissue biopsy can be performed. The sensitivity of 
routine smear-microscopy ranges from 20-80% (Steingart et al., 2007), culture 
takes several weeks to yield results, and suitable representative biological 
samples are frequently unobtainable either due to lack of sputum production or 
poor sample quality. This problem is increased by the HIV pandemic which 
increases the incidence of smear negative and sputum-scarce TB (Moore and 
Roper, 2007). Sputum induction is far less invasive, allows sampling of the lower 
airways in a non-invasive way (Vignola et al., 2002) and is equal in yield to 
bronchoscopy. In addition, it does not require substantial medical expertise or 
great expense. Sputum induction is especially useful in sputum-scarce or smear-
negative patients e.g. HIV-positive patients, as the saline irritates the airways 
forcing expectoration. In 1992 Pin et al. described the first standardised method 
for sputum induction using 3-5% hypertonic saline via a hypertonic nebulizer, to 
study inflammation in asthmatic patients (Pin et al., 1992).   
 
However despite all thes  methods, an effective and accurate rapid diagnostic 
tool is greatly lacking as TB still remains one of the leading global causes of 




Anti-TB treatment involves the use of a combination of drugs for 6 months, often 
following the directly observed treatment short course (DOTS) program. Multiple 
drugs are used in order to prevent resistance to one drug and also to maximize 











replicating bacteria while pyrazinamide is effective against bacteria located in 
acidic environments, inside macrophages or in areas of acute inflammation. 
Isoniazid, rifampicin, pyrazinamide and ethambutol are normally prescribed for 
two months, followed by isoniazid and rifampicin alone for a further four months. 
When the DOTS program is properly implemented, the success rate normally 
exceeds 95% and prevents the emergence of new multi-drug resistant TB 
strains. If no treatment is given fatality rates exceed 50% (Onyebujoh and Rook, 
2004). 
 
1.6 MULTI-DRUG RESISTANT TB (MDR-TB) 
 
In every country surveyed, MDR-TB has been documented. It is defined as TB 
which is resistant to the most powerful TB drugs (Rook et al., 2004), namely 
rifampicin and isoniazid. Resistance to all major TB drugs has emerged, however 
any combination not including the above-mentioned drugs is not classed as 
MDR. More recently in South Africa, “extensively drug-resistant tuberculosis“ has 
emerged. This is defined as MDR-TB that is resistant to quinolones and also to 
any one of kanamycin, capreomycin, or amikacin (WHO, 2006).  This strain of TB 











1.7 RATIONALE & OBJECTIVES 
 
Every year TB claims the lives of more than 2 million individuals worldwide. 
Rapid, accurate, and field-friendly diagnostic tools would contribute to quicker 
disease intervention and treatment. Indeed, deficiencies in current TB diagnostic 
tools may largely explain the low global case detection rate of about 62% (World 
Health Organisation, 2009). The development and evaluation of new diagnostic 
tools is a priority for the Global Stop TB Working Group on New Diagnostics. To 
prevent transmission of M.tb, prompt and accurate diagnosis is a matter of 
urgency. Keeler et al. estimated that 400 000 lives could be saved annually 
(Keeler et al., 2006).  
 
It is estimated that a third of the world’s population is infected with latent 
tuberculosis infection (LTBI). Although the TST is currently the only validated tool 
for diagnosis of LTBI its specificity is poor due to cross-reactivity with the BCG 
vaccination and non-tuberculous mycobacteria (NTM), and sensitivity is 
suboptimal in immuno-compromised individuals. Recently RD-1 antigen specific 
interferon-gamma release assays (IGRAs), namely T-SPOT®.TB and QFT-GIT 
have been developed. However, there is discordance both between the two 
commercial IGRAs and between the IGRAs and the TST which needs to be 
further explored. 
 
In addition to the difficulty of diagnosing LTBI, sputum scarce and smear-
negative TB poses great difficulty, which is exacerbated by the HIV pandemic. 
Sensitivity of smear microscopy is low, and culture takes several weeks. The 
yield of diagnostic methods is low and obtaining representative samples is often 
challenging (Dheda et al., 2009). Sputum induction is far less invasive than 
bronchoscopy and offers an equal if not higher microbiological yield. Additionally, 
it is far more patient-friendly and less expensive making it more suitable for 











diagnostic test. Although IGRAs have been designed for use with blood, the 
feasibility and diagnostic utility of this rapid immunonodiagnostic method using 
induced sputum in a high burden setting is unknown and needs to be 
investigated.  
 
More recently antigen-based diagnostic assays for TB have been developed. An 
ELISA-based assay using LAM has been tested in urine, cerebrospinal fluid, 
pleural fluid and expectorated sputum with moderate to poor success. The 
advantages of induced sputum may make it a more feasible sample for this 
immunodiagnostic assay. 
 
1.8 AIMS OF THE STUDY 
 
The aims of this study were: 
1. to investigate the discordance between the antigen-specific interferon-γ 
release assay (IGRA) and tuberculin skin test (TST) with quantitative PCR 
using skin biopsy samples, 
2. to evaluate the performance outcome of an RD-1 antigen-specific IGRA 
using cells from induced sputum for the diagnosis of M.tb infection, 
3. to evaluate the utility of lipoaraminomannan (LAM) detection via enzyme-
linked immunosorbent assays (ELISA) as a diagnostic test for M.tb  
infection using induced sputum.  
















GENERAL MATERIALS & METHODS 
 
 
2.1 Discordance study 
 
2.1.1 Subject recruitment 
Individuals in whom the tuberculin skin test (TST) was indicated were recruited in 
Cape Town, South Africa and in London, UK between May 2009 and March 
2010. Only individuals with no report of recent or current TB, or known 
immunosuppressive illness such as diabetes, cancer, hypertension, malnutrition 
or HIV/AIDS were included in the study. All recruits were over the age of 18 
years. Human participation was approved by the University of Cape Town Health 
Sciences Faculty Research Ethics Committee (REC reference number 
192/2008), and the research ethics committee for University College London 
Hospital (UCLH). Written informed consent was obtained from each participant. 
 
This project formed the beginning of a larger collaboration between the Infection 
& Immunity Department, University College London (Dr. M. Noursadeghi, UCL) 
and our Lung Infection and Immunity Unit, Department of Medicine, University of 
Cape Town (UCT). I visited there for two months to carry out the necessary 
laboratory work.  
 
2.1.2 Sample acquisition 
The TST was administered intradermally by the Mantoux method using 0.1ml 
(2U) of PPD RT23 (2-TU, Statens Serum Institut, Copenhagen, Denmark) into 
both forearms. Each injection site was marked with indelible ink. At the same 
time, 10ml of peripheral blood was drawn to perform the T-SPOT®.TB assay.  4-6 











before taking 2 x 3mm punch skin biopsies. The biopsies were symmetrically 
situated on either side of the marked injection site as close to each other as 
possible. 48 hours after initially administering the TST, 2 further skin biopsies 
were taken from the second forearm. 
 
Figure 2.1 Situation of the 2 x skin punch biopsies on either side of the TST 
intradermal injection on each forearm 
 
 
2.1.3 Sample processing 
2.1.3.1 Skin biopsies 
Two biopsies were taken on each forearm. The first biopsy was placed into an 
Eppendorf containing 1ml RNAlater buffer. The 2nd biopsy was embedded in 
Tissue-TEK® optimal cutting temperature (OCT) compound 4583 on a 20mm 
cork disc, then immediately frozen with cryospray, placed in a small durable 















All skin biopsies were stored at -80ºC until batched transport to UCL for further 
polymerase chain reaction (PCR). 
 
For PCR, RNA was purified from skin biopsies using the RNeasy lipid tissue kit 
(Qiagen). Quantitative expression profiling was performed using the RT² 
Profiler™ PCR Array system with customised primer sets 
(http://www.superarray.com). The following genes were included in the analysis: 
 
1. Markers of innate dendritic cell/ macrophage activation e.g. TNFα, IL-1β, 
IL-8, IL-12; 
2. Markers of T-cell activation and proliferation e.g. IL-2; 
3. Markers of T-helper1 (Th1)-type response e.g. IFN-γ, IL-12, Tbet 
4. Markers of T-helper2 (Th2)-type response e.g. IL-4, GATA3 
5. Markers of T-helper17 (Th17)-type response e.g. IL-17A, RORc 
6. IFN-γ response genes in dendritic cells and macrophages e.g. IRF1 
 





The blood was transported immediately to the Lung infection & Immunity Unit, 













50ul of antigen (ESAT-6 and CFP-10) and phytohaemaglutinin (PHA) was added 
to duplicate wells followed by 250 000 cells made up in 100ul media (wherever 
possible). All samples underwent overnight stimulation at 37°C in a humidified 
5% CO2 incubator. Spot-forming cells (SFCs), representing IFN-γ release by 
peptide-specific T cells, were counted with an automated AID-ELISPOT reader 
system (Autoimmun Diagnostika, Strassberg, Germany). Simultaneously SFCs 
were counted manually to confirm the accuracy of the machine as induced 
sputum SFCs have an irregular appearance (see Figure 4.3). The mean of 
duplicate numbers of SFCs determined the reactivity of the assay. The results 
were classified as either positive or negative as per the pre-defined guidelines 
described in chapter 1. 
 
2.1 Induced sputum study 
 
2.2.1 Subject recruitment 
TB suspects were recruited from Langa and Chapel Street Primary Health Care 
Clinics, and the Respiratory Clinic at Groote Schuur Hospital in Cape Town 
between March 2008 and April 2009. Study inclusion criteria included possible 
TB based on clinical examination in subjects who had not commenced TB 
treatment and were over 18 years of age. All the enrolled patients had a chest x-
ray, which was reported by at least one pulmonologist, and subsequent treatment 
was continued independently of the research laboratory findings. Human 
participation was approved by the University of Cape Town Health Sciences 
Faculty Research Ethics Committee (REC number 421/2006), and written 















2.2.2 Sample acquisition 
Individuals were requested to rinse their mouth in order to reduce the risk of 
contamination with salivary squamous epithelial cells and mouth flora. Strict 
infection control measures were followed during all acquisition and processing of 
sputum samples. The patient was then seated in an enclosed, negative-pressure 
sputum induction booth. Approximately 20ml of sterile 5% hypertonic saline 
(Sabax, Adcock Ingram Critical Care (PTY) LTD, Johannesburg, South Africa) 
was delivered via a Wilson’s 402A ultrasonic nebuliser (Medimark, South Africa) 
over a period of 15 minutes or until 4-12ml of induced sputum could be collected 
in a sterile container. No pro-expectorating manoeuvres, such as chest 
percussion, were employed. Induction was immediately terminated if side effects 
such as dyspnoea, chest discomfort or nausea were reported. After sputum 
induction, the samples were transported to the Lung Infection & Immunity 
Laboratory, Groote Schuur Hospital and processed within 2 hours. An aliquot of 
each sample was processed at the National Health Laboratory Services (NHLS) 
microbiology laboratory, at Groote Schuur Hospital. Smear microscopy was 
performed by auromine-O staining for acid-fast bacilli (AFB). All samples were 
cultured for mycobacterium and other pathogens (MGIT 960). 
After the results were obtained from the NHLS, the following criteria were used 
for diagnostic classification: 
 
1. Definite TB: A clinical presentation compatible with TB with at least 1 
positive culture (from any specimen) for M.tuberculosis with response to 
anti-TB therapy (Wilson et al., 2006). 
2. Probable TB: A clinical-radiological picture highly suggestive of TB and/or 
anti-TB treatment initiated by the attending clinician based on clinical 











3. Non-TB: no evidence of TB based on smear microscopy and culture, and 
no radiological evidence to support the diagnosis of active TB, with or 
without an alternative diagnosis being established on patient follow-up. 
4. Indeterminate TB: either the culture or chest x-ray results (or both) were 
unavailable, and the patient was lost to follow-up or transferred to another 
centre, thus making it impossible to confidently rule-out or rule-in TB. These 
patients were excluded from the analysis. 
 
2.2.3 Sample processing 
2.2.3.1 Processing of induced sputum 
An optimization phase was first completed given the paucity of established 
processing methods of induced sputum for ELISPOT assays.  
 
All induced sputum samples were processed using a protocol based on that used 
by Bhowmik et al. (1998) with minor modifications to isolate mononuclear cells 
which could be plated in the T-SPOT.®TB wells and developed as per the 
manufacturer’s instructions. 
 
Homogenization with 0.1% dithiothreitrol (DTT, Sigma, UK) was performed upon 
arrival of the sample in the laboratory. The optimal volume and rolling time for 
solution, dilution and homogenization was determined by the sample’s final 
macroscopic appearance, viability of the induced sputum mononuclear cells and 
the degree of background discoloration in the T-SPOT®.TB (Oxford Immunotec).  
 
Immediately after homogenization, the sample was either filtered through 2-ply 
sterile gauze, a 100µm cell strainer, or separated using Histopaque-1077 
(Sigma). Sputum mononuclear cells were isolated by centrifugation at 1200rpm 











The highest viable cell count with the least particulate and unwanted matter 
retained determined the optimal filtration method.  
 
To determine the optimal number of cells to be used per ELISPOT well, 
mononuclear induced sputum cells from 3 subjects were plated in duplicate wells 
at concentrations of 1x104, 2.5x104, 5x104, 1x105, 2.5x105 and 5x105 cells/well. 
The mean number of spot-forming cells (SFCs) for each concentration was 
calculated, and the optimal number of cells per well was determined.  
 
The final method used was dilution of the induced sputum with 2 x volume of 
0.1% DTT. After rolling for 20 minutes, the sample was filtered and washed twice 
with PBS. An aliquot was sent to the NHLS for microbiological testing (Gram and 
acid fast staining as well as TB culture).  The non-cellular fraction was drawn off, 
while the remaining mononuclear cells were resuspended in 1-2 ml AIM-V® 
medium (Gibco, Invitrogen) and counted using a Neubauer haemacytometer 
chamber.   
 
2.2.3.2 T-SPOT®.TB-assay 
Induced sputum mononuclear cells were used in the T-SPOT®.TB assay as 
explained above in section 2.1.3.2. 
 
2.2.3.3 LAM-specific techniques 
4-10ml of the non-cellular fraction of the induced sputum was aliquoted into a 
15ml tube and incubated in a waterbath at 95ºC for 30 minutes. After cooling to 
room temperature, the sample was centrifuged at 300g for 15 minutes to remove 
any solid particles and unwanted matter. 2 x 1.5mls aliquots of supernatant were 












To process, the samples were thawed at room temperature. In order to detect 
and measure the LAM amount in each sample, the Clearview® TB ELISA 
(Inverness Medical Innovations Inc, Scarborough, ME, USA) point-of-care ELISA 
strip kit was used. 100μl of processed sputum was added to the pre-coated wells 
including the relevant positive and negative controls. All controls, standards and 
samples were added in duplicate. The plate was then sealed with the self-
adhesive plastic film provided in the kit and incubated at 24ºC in an air-
conditioned room for 60 minutes.  
 
The well contents were decanted into a wash-basin and the plate firmly tapped 
over a paper towel to remove any residual liquid. The wells were then manually 
washed 4 times with 250μl of prepared wash solution. 100μl of LAM-specific 
polyclonal antibody conjugated with horseradish peroxidase was added to the 
wells, at the same rate and sequence as the initial loading of the samples. The 
incubation and wash steps, as described above, were repeated. After washing a 
further 4 times, 100μl of tetramethylbenzidine (TMB) single component 
chromogenic substrate solution was added to the wells at the same initial rate 
and sequence. The plate was re-sealed and incubated at room temperature for 
15 minutes. The reaction was stopped by adding 100μl of 1 molar sulphuric acid 
(in-house) to the plate at the same rate and in the same sequence as the TMB 
solution. Gentle shaking of the plate at each stage ensured there were no air 
bubbles and that the well contents were properly mixed. 
 
Absorbance was measured at 450nm, single wavelength. Based on the standard 
curve established for each experimental plate, the OD reading was used to 
calculate the sample’s LAM concentration. The assay results are calculated as 
per the manufacturer’s instructions, the cut-off value was determined by the sum 
of 0.1 and the mean OD value of the negative control well. All samples with a 
mean OD above the cut-off value were defined as positive for LAM. Interpretation 











2.2.3.4 Protein quantification in induced sputum 
The LAM-containing non-cellular fractions were isolated from varying volumes of 
induced sputum so had to be normalised for volume, total number of cells and 
protein concentration. In order to measure the protein content of the samples the 
Bio-Rad Protein Assay Kit II, 500-0002 (Bio-Rad Laboratories, 2000 Alfred Nobel 







Figure 2.3. Bio-Rad Protein Assay Kit II, 500-0002 
 
The dye reagent of the Bio-Rad protein kit was prepared by diluting the dye 
reagent concentrate with double distilled water at a ratio 1:4. The prepared dye 
was filtered through Whatman #1 filter paper to remove any particulates. Six 
serial dilutions of bovine serum albumin, 1.45mg/ml (the protein standard), were 
prepared with double distilled water to serve as standards for the ELISA assay. 
All standards and samples were plated in duplicate. 
 
Ten microlitres of each standard and sample solution was loaded into separate 
microtiter wells of a Greiner, flat-bottomed plate. 200μl of diluted dye reagent was 
added to each well in the same sequential order to ensure timing remained 
constant. The samples and reagents were covered with aluminium foil to protect 











room temperature for 5-60 minutes. The Bio-Rad protein assay was read at 













THE DISCORDANCE BETWEEN THE TUBERCULIN SKIN TEST (TST) AND 
INTERFERON GAMMA RELEASE ASSAY (IGRA) 
 
INTRODUCTION 
One third of the world is infected with TB, yet only 10% of these will develop 
active TB. The immune system may contain the infection to keep the individual 
symptom free (Kaufmann, 2006). To date the TST, which was introduced in 
1890, has been relied upon to diagnose LTBI. The TST contains an extract of 
cultured filtrate called purified protein derivative (PPD). 
 
The TST is cumbersome to perform, and may be affected by BCG vaccination, 
recent TST administration (van Zyl-Smit et al., 2009), environmental 
mycobacterial exposure and anergy in individuals who are immunosuppressed 
(Dheda et al., 2005), thus confounding interpretation of the results. The reading 
of the TST is prone to reader variability when interpreting the induration width 
(Huebner et al., 1993), and requires a second visit to be read. 
 
More recently, interferon gamma release assays (IGRAs) have been developed 
using more M.tb-specific antigens [early secretory antigenic target-6 (ESAT-6) 
and culture filtrate protein -6 (CFP-10)] in an attempt to overcome several of 
these issues.  The principle underlying these assays is that T-cells, previously 
sensitised to tuberculous antigens, will produce IFN-γ upon re-encountering M.tb-
specific antigens (Pai et al., 2007). IGRAs have been found to be advantageous 
over the TST in terms of their higher specificity in persons previously BCG 
vaccinated, particularly after birth. The results of the IGRA may be less 











It has been well documented that the agreement between the TST and IGRA is 
not 100%. A meta-analysis by Pai et al. showed an overall agreement of only 60-
80% between the two tests and kappa (k) statistics were highly inconsistent 
ranging from -0.03 to 0.87 (Pai et al., 2004). Similarly, Menzies et al. reported a 
discordance of 29% between the TST and Quantiferon (QFT) assay (Menzies et 
al., 2007).  
 
There are two types of discordance namely TST-positive, IGRA-negative and 
TST-negative and IGRA-positive. Please see the introduction for more detail. 
Briefly, a false positive TST can be due to prior BCG vaccination, or previous 
exposure to NTM, while a false negative result could occur in immunosuppressed 
patients such as those with HIV/AIDS or taking chemotherapy, diabetics or 
malnourished individuals. A positive IGRA with negative TST could indicate LTBI, 
and we hypothesize that a false negative IGRA could result from the 
immunosuppressive effects of regulatory T cells or cytokines such as IL-4, IL-9 or 
IL-10. 
 
Despite much literature describing the discordance between the IGRA and TST 
(Arend et al., 2007; Ferrara et al., 2006; Lee et al., 2006), there are very few 
studies investigating the underlying mechanisms. I hypothesized that in TST+ve/ 
IGRA-ve discordant subjects the immunological profile in a skin biopsy is 
different from that of a TST+ve/ IGRA+ve and TST-ve/ IGRA-ve individual and 
represents a distinct immunodiagnostic entity which may give insight into the 
immunopathogenesis of discordance. This study aimed to use quantitative PCR, 
to investigate the correlation between the immunohistological profiles of TST skin 
biopsy samples and IGRA status.  Of the two subsets of discordance which have 












MATERIALS & METHODS 
 
Human subjects and sample processing 
A total of 20 individuals were enrolled in the prospective cohort study. 12 
individuals were recruited in Cape Town, South Africa, and the remaining 8 were 
from the Department Infection & Immunity, University College London Hospital 
(UCLH), UK under the direction of Dr Mahdad Noursadeghi. Please refer to 
Chapter 2 for details concerning the recruitment and specific methodologies of 
the TST and T-SPOT®.TB assay. 
 
Briefly, a TST was administered to both forearms of all individuals in the study. 
(At the same time 10ml of peripheral blood was drawn to be processed in the T-
SPOT®.TB assay.) 2 x 3mm punch skin biopsies were taken from either side of 
the TST injection site on one forearm. 48 hours later, the TST was read and an 
additional two punch skin biopsies were taken from forearm 2.  
 
The induration diameter was recorded as positive if it measured > 5mm. Positive 
and negative categories were then cross-referenced with those of the T-
SPOT®.TB assay thereby categorizing samples as follows: 
• TST positive and T-SPOT®.TB positive (+/+); or  
• TST positive but T-SPOT®.TB negative (+/-); or  
• TST negative and T-SPOT®.TB negative (-/-); or 















PCR analysis  
qPCR was used to evaluate the changes in levels of specific cytokines and 
transcription factors over the 48 hour time period. The qScript cDNA Supermix kit 
(Quanta BioSciences) was used to synthesize first strand cDNA. Quantitative 
PCR (qPCR) was performed using the Mastercycler Realplex 4 (Eppendorf) with 
inventoried TaqMan assays as follows: 
 




















For these assays, the TaqMan Gen Expression Mastermix (Applied Biosystems) 
was used according to the manufacturer’s instructions. The glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as a housekeeping gene to 
normalise the expression of the relevant cytokines. The 48-hour biopsies had 
higher levels of GAPDH. Yet this was not due to fluctuation with time, but rather 
due to the amount of RNA template added. The RNA concentration which was 
used for cDNA synthesis was not standardised and RNA levels were higher in 
the 2nd biopsy.  
 
 



























Discordance between the IGRAs and the TSTs was compared using appropriate 
parametric and non-parametric statistical tests with GraphPad Prism version 4.0 














Twenty individuals were enrolled in the study, 12 from Cape Town, South Africa 
and 8 from London, UK. The T-SPOT®.TB results of 3 UK individuals were invalid 
due to a non-reactive positive control well. Thus, these samples were excluded 
from the study. As the UK cohort was very small, and they were relatively equally 
distributed across all of the pre-defined sub-groups, all results were pooled for 
analysis purposes. Three (17.6%) individuals were TST-positive, T-SPOT®.TB 
positive (+/+), 5 (29.4%) were TST-positive, T-SPOT®.TB negative (+/-), the 
majority [8 (47%)] were TST-negative, T-SPOT®.TB negative (-/-) while 1 (5.9%) 
individual was TST-negative, T-SPOT®.TB positive (-/+). However, the last-
mentioned category could not be considered as it contained only 1 sample. See 
table 3.1. 
 
Demographics of the patients 
There was an equal distribution of TST-positive and TST-negative individuals i.e. 
8 in each category. The mean (SD) age of individuals in the +/+ subgroup was 
39.3 years (4.5years), the +/- subgroup showed a mean age (SD) of 40.8 years 
(10.1 years), and the mean (SD) age in the -/- subgroup was 35.9 years (7.3 
years). 35% of the overall cohort were male, and all were HIV-negative. Of the 17 
individuals included in the study, 3 (17.6%) were black African, 6 (35.3%) of 


























      
Age (SD)      
 39.3 (4.5) 40.8 (10.1) 35.9 (7.3) 22  
  
Gender      
Male 0 2 (40%) 3 (37.5%) 1 p= 0.93 
  
Ethnicity      
Black African 1 2(40%) 0 0  
Mixed Ancestry 2 (66.6%) 1 3 (37.5%) 0  
European 
Ancestry 0 2(40%) 4(50%) 0  
Other 0 0 1 1  
  











11-15mm 0 0 0 0  
16-20mm 0 1 0 0  
21-25mm 1 3 (60%) 0 0  
>25mm 2 (66.6%) 1 0 0  
  
BCG vaccination      
Yes 3 (100%) 5 (100%)* 7 (87.5%)* 1 *p=0.25 
  
Exposure to 
NTMs      
 1 (33.3%) 0 1 (12.8%) 0  
  
HIV Status   
 All subjects were HIV negative  
  
Previous TB      
Yes 1(33.3%) 0 0 0  
 
+/+ = TST positive, T-SPOT®.TB positive; +/- = TST positive, T-SPOT®.TB negative; 
-/- = TST negative, T-SPOT®.TB negative; -/+ = TST negative, T-SPOT®.TB positive 
 
 
TST  results 
All TST results were measurable and all individuals returned for TST reading. 











categorized as positive. A total of 8 individuals tested TST-positive (47%). When 
comparing their mean (SD) age of 41.6 (8.45) years to that of the total cohort 
(37[8]), there was no significant difference (P=0.23).  
 
Of the TST-positive individuals, all had been BCG vaccinated. The median TST 
diameter of the samples from RSA was 22.5mm (range: 0-52mm) compared to 




















Figure 3.1 Median TST diameter of the South African cohort compared to the 
median of the cohort of the UK samples. Horizontal lines depict median values. 
 
PCR results 
The underlying cytokine changes were assessed over the 48 hour time period 








































































































Figure 3.2 The cytokine changes across the 4 pre-defined subgroups compared 
over 48 hours. The horizontal lines depict median values.  Closed symbols 
represent the first biopsy, while open symbols represent the second biopsy at 48 
hours. 
+/+1st/2nd = Biopsy 1or 2 in TST positive, T-SPOT®.TB positive subgroup; 
+/-1st/2nd = Biopsy 1 or 2 in TST positive, T-SPOT®.TB negative subgroup; 
-/-1st /2nd= Biopsy 1or 2 in TST negative, T-SPOT®.TB negative subgroup;  





















































































































































Figure 3.2 The cytokine changes across the 4 pre-defined subgroups compared 
over 48 hours. The horizontal lines depict median values.  Closed symbols 











































































































Figure 3.2 The cytokine changes across the 4 pre-defined subgroups compared 
over 48 hours. The horizontal lines depict median values. Closed symbols 
represent the first biopsy, while open symbols represent the second biopsy at 48 
hours. 
+/+1st/2nd = Biopsy 1or 2 in TST positive, T-SPOT®.TB positive subgroup; 
+/-1st/2nd = Biopsy 1 or 2 in TST positive, T-SPOT®.TB negative subgroup; 
-/-1st /2nd= Biopsy 1or 2 in TST negative, T-SPOT®.TB negative subgroup;  
-/+1st/2nd =Biopsy 1 or 2 in TST negative, T-SPOT®.TB positive subgroup 
 
All subgroups show an increase in IFN-γ and Tbet indicating a Th1-type immune 
response. GATA3 (p=0.004) and IL4 (p=0.0008) increase over the 48 hour time 











mixed Th1/Th2 response.  These may dampen the Th1-type immune response 
accounting for a false-negative IGRA in +/- subgroup. IL-17A and RORc 
increased significantly (p=0.0008 and p=0.04 respectively). Additionally FoxP3 
increased in the +/- subgroup (p=0.0008) while it remained unchanged in the 
other subgroups. The +/- subgroup showed the greatest change in IL-1β 
(p<0.0001) and TNF-α (p=0.0002), both cytokines being associated with DC and 
macrophage activation causing inflammation. IL-8 showed no change in any of 
the subgroups. When comparing the cytokine changes of the individual 
subgroups it was evident that the cytokine pattern at baseline biopsy differed 
between all 3 groups.  
 
Table 3.3 Change in mean cytokine level within each concordant/ discordant 
subgroup over 48 hours. I.e. Change from the 0 to 48 hour time point. 
 
  +/+ -/- +/- p – value comparing  0 and 48 hours 




 Tbet 2.89 2.58 6.33* 0.005* 
 TNF-α 2.32 1.49 3.27* 0.0002* 
 IL-1β 2.86 2.11 3.77* <0.0001* 
      
Th2-type response IL-4 3.87§ 1.75 2.62* 0.04* 0.0008§ 
 GATA3 -4.54§ 1.44 7.43* 0.004* 0.03§ 
      
Th17-type response IL-17A 3.46 1.27 4.61* 0.0008* 
 RORc -1.93 -0.25 2.62* 0.04* 
      
FoxP3-type response FoxP3 1.96 1.33# 4.61* 0.0008* 0.01# 
 
Concordant and discordant grouping by TST/ T-SPOT® TB. Only 1 individual was 
TST-ve /T-SPOT® TB+ve and thus not included in the analysis. Only significant 
p-values are indicated. (Note if correction for multiple comparisons is performed, 
only p values of <0.025 should be considered significant.) 
§ = p-value in the +/+ subgroup; # = p-value in the -/- subgroup 











Comparison of the 48 hour biopsy cytokine responses across all three subgroups 
was done using a 1-way ANOVA, Kruskal-Wallis test with Dunn’s post- test for 
multiple comparisons. There was a significant difference in IFN-γ (p=0.003) IL-1β, 
(p=0.01), IL-17A (p=0.005), GATA-3 (p=0.03) and FOXP3 (p=0.008). When 
comparing individual groups there was a significant difference between +/+ vs. -/- 
for IL-1β (p<0.05), IL17-A (p<0.01), +/+ vs. +/- for FOXP3 (p<0.05) and for -/- vs. 
+/- FOXP3 (p<0.05) and GATA-3 (p<0.05). The cytokine pattern at the 48 hour 
time point of each subgroup was unique. See table 3.3.  
 
Table 3.4 Comparison of mean ∆CT GAPDH-GOI values measured between 
concordant/ discordant subgroups at the 48 hour time point. 
 
  +/+ -/- +/- p – value at 48 hours  
Th1-type response IFN-γ -6.89 -11.69 -6.97 0.03 
 Tbet -8.66 -9.77 -11.82 0.13 
 TNF-α -4.83 -5.92 -4.81 0.18 
 IL-1β -5.10* -8.98* -6.64 0.01 
      
Th2-type response IL-4 -16.13 -18.25 -17.38 0.43 
 GATA3 -4.70 -3.85* -6.97* 0.03 
      
Th17-type response IL-17A -13.97* -18.73* -15.39 0.005 
 RORc -16.61 -15.04 -17.38 0.83 
      
FoxP3-type response FoxP3 -8.33# -8.84* -15.39*# 0.008 
 
The comparison was done using the 1-way ANOVA, Kruskal-Wallis test.*, # 














The TST has for a long time been the only diagnostic test for LTBI. The newer 
IGRAs have been shown to be more specific but given the lack of a gold 
standard, it remains difficult to be certain of the assay’s specificity for detecting 
latent TB infection. In addition, the discordance rates of up to 40% (Pai et al., 
2004) remain poorly explained. This study had a comparable discordance rate of 
35% (6/17). 
 
When looking at the change in cytokine levels over 48 hours, those in the +/+ 
subgroup are similar to those in the -/- subgroups, with the exception of IFN-γ 
and IL-4. The significantly raised IFN-γ response (p=0.03) in the +/+ subgroup 
would be expected as we believe that these individuals had LTBI. The increased 
Th2-response could possibly be explained by findings described by Rook et al.  
who showed that individuals living in Africa may have strong Th2-type immune 
responses to TB with increased levels of IL-4 (Rook, 2007). The -/- subgroup 
shows a modest, mixed response with IFN-γ and FoxP3 showing a significant 
increase (p=0.04 and p=0.01 respectively). Yet both TST and IGRA are negative. 
Perhaps this is because PCR is a more sensitive tool. It has been suggested that 
our available tools lack the sensitivity to detect LTBI (Dheda et al., 2010). The T 
cells in the skin are possibly more cross-reactive than those in peripheral blood, 
also making this test more sensitive. Additionally, LTBI may be a spectrum of 
infection. The level of infection may have been insufficient to be detected by 
either TST or IGRA but due to the sensitivity of PCR, a response is detected in 
those thought not to be infected by conventional testing. Further studies are 














In the +/- discordant subgroup, however, there were significant changes in all 
Th1, Th2, Th17 and FoxP3-type responses. As TB drives a Th1-type response, 
these increases could be expected, yet the IGRA is negative. This could be LTBI 
with a false negative IGRA due to remote or low burden infection. Alternatively, 
the host genotype may predict unresponsiveness to ESAT-6 and CFP-10 due to 
pattern recognition profiles. 
 
 
TB typically elucidates a Th1-type response, so an increase in IFN-γ, IRF-1, 
associated with macrophage response to IFN-γ, and Tbet in all subgroups could 
be expected. However, in the +/- subgroup, a Th2-type immune response is 
apparent: GATA3 (p=0.004) and IL4 (p=0.0008) increase over the 48 hour time 
period.  These may suppress the Th1-type cytokines believed to be responsible 
for a positive IGRA by driving a Th2-type immune response. The increase in IL-
17A and RORc and FoxP3 is also unique to the +/- subgroup. IL-17A and RORc 
favour a T-helper 17 (Th17) response. In addition to it’s pro-inflammatory effect, 
Th17 may be targeted against extracellular bacteria (Tato and O'Shea, 2006). 
Fox-P3 characterizes regulatory T cells (Tregs) which suppress a variety of 
immune responses (Fontenot and Rudensky, 2005). Tregs contribute to the 
persistence of M.tb in vivo by suppressing antibacterial immune responses 
(Guyot-Revol et al., 2006; Lundgren et al., 2005). It is possible that the 
immunosuppressive effects of Tregs together with Th17- and Th2-type cytokines 
may explain the TST+ve/ IGRA-ve discordance. The above-mentioned changes 
in cytokines and transcription factors could be responsible for an 
immunosuppressive effect on IGRAs, thus resulting in false negative results. 
These observations need to be confirmed in antigen-stimulated PBMCs. 
 
The PCR results suggested that the baseline cytokine levels were different in all 
3 subgroups. Similarly the cytokine levels at the 48-hour time point were unique 











patterns in his study of ESAT-6 stimulated cytokines over a 24-hour time period 
(Nemeth et al., 2010). Thus, in the TST+ve/IGRA-ve discordant subset the 
immunological profile in a skin biopsy differed from that of the TST+ve/IGRA+ve 
and TST-ve/IGRA-ve subgroups. This represents a distinct immunodiagnostic 
entity which may give insight into the immunopathogenesis of discordance. PCR-
analysis of the +/- discordant subgroup showed cytokine changes confirming 
activity of Tregs and Th2-like cytokines. These effects could all contribute to a 
false negative T-SPOT®.TB, possibly explaining the discordant +/- subgroup.  
 
An alternative explanation for TST+ve/ IGRA-ve discordance is false TST 
positivity. The TST measures cell-mediated immunity in the form of delayed-type 
hypersensitivity response to PPD so is positive whenever the host has previously 
been exposed to mycobacterial antigens. This could result from prior BCG-
vaccination, previous exposure to TB, or exposure to some NTM. The overlap in 
genetic sequence between various NTM and M.tb may result in a false positive 
result. NTM are generally an important cause of false-positive TST in populations 
with a very low prevalence of TB infection and high prevalence of NTM 
sensitisation. However, Farhat et al. suggest that only 2% of individuals would 
have false positive TSTs after exposure to NTM (Farhat et al., 2006). If 
vaccinated at 2 years or older, the BCG vaccine could be responsible for up to 
20% of false positive results (Farhat et al., 2006). Nevertheless, in developing 
countries BCG vaccination occurs at birth and may thus explain a false positive 
TST in this context. 
 
The incidence of TB is far greater in developing, high burden countries. In South 
Africa 461 000 new cases are reported annually compared to only 9 000 in the 
UK (World Health Organisation, 2009). Consequently, the South African 
population will be far more exposed to mycobacteria and have a far greater 
chance of contracting infection. In this case the TST may be more highly 











being 22.5 (range: 0-52mm) compared to that of the UK population at 5mm 
(range: 0-18mm) See Figure 3.1. All individuals in this study had been BCG-
vaccinated at birth. 
 
Inclusion of an additional antigen in the IGRA which may be associated with 
disease or latency may prove useful. A novel antigen such as heparin-binding 
haemagglutinin (HBHA) may be such a possibility. It has been shown to be more 
sensitive than ESAT-6 and more specific than PPD for the detection of LTBI in 
small studies. In addition it was not influenced by BCG status of the individual 
(Hougardy et al., 2007).  
 
IGRAs have been designed for the diagnosis of LTBI though their sensitivity and 
specificity for this purpose, particularly in high burden settings is controversial. 
Whilst the study of TST/IGRA responses may shed important light on 
immunopathogenesis, the real clinical challenge in high burden settings is the 
diagnosis of active TB. This is discussed in the following chapters. 
 
This study served as a pilot study for possible further more detailed work on the 
discordance between the TST and IGRA. Although the results of this study 
appear promising and interesting, the sample size was very small. Larger studies 













FEASIBILITY and DIAGNOSTIC UTILITY of ANTIGEN-SPECIFIC 
INTERFERON-γ RESPONSES for RAPID IMMUMODIAGNOSIS OF 




Multiple factors severely hamper efforts to control TB. The sensitivity of routine 
smear-microscopy is approximately 50% (Cattamanchi et al., 2009), culture 
techniques take several weeks to yield results, and suitable representative 
biological samples are frequently unobtainable either due to lack of sputum 
production or poor sample quality. This problem is compounded by the HIV 
pandemic which increases the incidence of smear-negative and sputum-scarce 
TB (Moore and Roper, 2007). 
 
Alternative techniques to obtain pulmonary samples are required in these 
patients such as sputum induction, gastric washings and bronchoscopy (Brown 
et al., 2007; Dheda et al., 2009; Schoch et al., 2007). However, gastric washings 
are largely limited to use in children while bronchoscopy is expensive, invasive 
and not widely available in resource-limited settings.  In contrast, sputum 
induction has been shown to be safe, well tolerated and non-invasive and is 
more cost-effective than bronchoscopy for pulmonary TB diagnosis (Bhowmik et 
al., 1998; Fishman et al., 1994; Hartung et al., 2002; McWilliams et al., 2002; 
Parry et al., 1995). Additionally, it has been shown to provide an equal, or higher 
microbiological yield when compared to bronchoscopy (Breen et al., 2007; Conde 
et al., 2000; Robinson et al., 1985) and is superior to gastric washings regarding 











It is possible to collect more than one induced sputum sample on the same day 
resulting in faster diagnosis, treatment and a subsequent shorter hospital stay 
(Brown et al., 2007). Hartung et al. showed that induced sputum may diagnose 
TB in 29% of suspects who were either smear negative or sputum-scarce 
(Hartung et al., 2002). Smear results from sputum induction and broncho-alveolar 
lavage (BAL) agreed in 75% of cases (Ganguly et al., 2008). Moreover, the 
predictive value of negative induced sputum culture has been shown to be 
approximately 96% (Andersen et al., 2000). Yet rapid diagnosis of 
Mycobacterium tuberculosis is still frequently impossible given the low yield of 
smear microscopy, approximately 7-32% in this context (McWilliams et al., 2002; 
Morse et al., 2008). 
 
In resource-limited settings, therefore, the use of sputum induction could provide 
an ideal patient-friendly option. Being less costly, it is a more feasible option for 
primary healthcare clinics where the first possible contact for diagnosis of TB 
takes place. Multi-drug resistant (MDR) TB and extensively drug resistant (XDR) 
TB are becoming progressively more prevalent (Bell et al., 2003; Dheda et al., 
2010). Furthermore, the WHO 2009 TB report indicated that 23% of the 
estimated 2 million HIV deaths in 2007 were due to TB. Thus early diagnosis is 
especially important in these two population groups. Sputum induction is 
particularly useful for smear-negative patients, e.g. HIV-positive patients, and for 
those who are unable to expectorate. 
 
More recently, the IGRAs have been developed. There are currently two formats, 
an ELISPOT, and an ELISA. IGRAs have been shown to be highly sensitive and 
specific blood tests for the diagnosis of latent M.tb infection (Dheda et al., 2005; 
Pai et al., 2008). These rapid, in vitro immunoassays measure IFN-γ release by 
antigen-specific effector memory T cells after stimulation by M.tb-specific 
antigens [early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-











The commercially available IGRA (T-SPOT®.TB) (Oxford Immunotec, Oxford, 
UK) uses an ELISPOT format with the standardised TB-specific-antigens to 
accurately diagnose latent TB infection. Although IGRAs are more commonly 
used to detect IFN-γ release from peripheral blood T-cells, they have been 
successfully shown to be an accurate tool for the rapid diagnosis of active TB 
using cerebrospinal fluid mononuclear cells (Patel et al., 2009), and BAL cells 
(Jafari et al., 2009; van Zyl-Smit et al., 2010). Thus, it appears that the ELISPOT 
assay can be accurately used to diagnose active TB using cells from the site of 
disease. So I hypothesized that mononuclear cells isolated from induced sputum 
could be used in the ELISPOT assay to diagnose pulmonary TB. 
 
However, there are no data reporting the use of induced sputum using the 
ELISPOT assay in any population. Therefore, the aim of this study was to 
determine the feasibility and performance outcome of the RD-1-ELISPOT to 
diagnose tuberculosis using induced sputum mononuclear cells in a high TB-
















MATERIALS & METHODS  
 
A prospective cohort study including one hundred and one patients, in whom 
sputum induction was indicated, was performed. Please refer to chapter 2 for 
further details about patient recruitment and sample processing.  
 
Briefly, induced sputum was obtained from TB suspects and processed within 2 
hours. 28 individuals were included in an optimisation phase to determine the 
best method of isolating mononuclear cells from induced sputum to be used in an 
ELISPOT assay. The optimal homogenisation and filtration method, centrifugal 
speed and number of cells to be plated per ELISPOT well were determined. A 
validation phase based on these findings followed. The cells were plated in 
duplicate and incubated overnight with the antigens ESAT-6, and CFP-10. The 
number of spots seen in each well represents IFN-γ release by peptide-specific T 
cells and determines the reactivity of the assay. Diagnosis of TB was based on 
the number of spots/well according to the manufacturer’s guidelines for 
peripheral blood mononuclear cells.  
 
Statistical analyses 
Results of the IGRAs were compared with diagnoses made by conventional 
microbiological sputum staining and bacterial culture. The number and reasons 
for indeterminate tests were recorded. Categorical variables were compared 
using the Chi-Squared analysis; continuous variables were compared using 
Students’-T test when normally distributed and the Mann-Whitney test for non-
parametric distribution. A p-value of 0.05 or less was considered significant. 
GraphPad Prism (version 4.0 or higher) for Windows (Graphpad Software, San 













Demographics of the validation phase patients 
The validation phase included 73 patient samples. 5 individuals were excluded 
as patient side-effects necessitated terminating sputum induction prematurely. 
The mean (SD) age of the definite, probable and non-TB groups was 38 (15) 
years, 48 (10) years, and 49 (17) years respectively. Approximately half of the 
cohort was male, with the probable TB group having the highest percentage 
(75%) of individuals. Similarly, the probable TB group also had the highest 
number of HIV-positive individuals (75%). Of the 68 samples, 20 were diagnosed 
with definite of probable TB while 48 had non-TB (Table 4.1). 
 
Table 4.1. Demographic information of patients included in the validation phase 
excluding 5 patients in whom sputum could not be induced. 




Number of subjects 68 16(23%) 4 (6%) 48 (71%)  
      
Age mean(SD) 46 (17) 38 (15)  48 (10) 49 (17) p=0.03 
      
Sex      
      Male 33(49%) 10(63%) 3(75%) 20(42%) p=0.14 
      
Racial group      
      Black African 29(43%) 9 (56%) 3(75%) 17(35%) p=0.14 
      Mixed Ancestry 35(51%) 7 (44%) 1(25%) 27(56%) p=0.39 
      European Ancestry 4(6%) 0 0 4(9%)  
      
Current smoker  20 (29%) 5 (31%) 2(50%) 13(27%) p=0.75 
      
HIV status      
      positive 20 (29%) 7 (44%) 3(75%) 10 (21%) p=0.09 
unknown/ refused      
testing 10 (15%) 0 0 10 (21%)  
      
Previous TB (n=54) 16(24%) 5(31%) 2(50%) 9(19%) p=0.29 











Each patient was nebulized with 5% hypertonic saline for 5-20 minutes or until an 
acceptable sample could be obtained. The median volume of induced sputum 
was 7ml (range: 4-12ml). Eight patients produced ≤ 1ml which was considered 
inadequate for further processing. 
 
Optimization phase 
The optimization phase included 28 TB suspects. It was found that by adding 2 x 
volume of 0.01% DTT solution to the induced sputum sample, and rolling the 
suspension for 20 minutes, the mucins were sufficiently digested to dissolve and 
homogenize the sample. This volume neither destroyed the mononuclear cells 
nor contributed to background discoloration of the assay. An increased length of 
mixing time was tested if dissolution and/or homogenization were inadequate. 
This did not significantly alter the mucus content and viscosity of the sample. In 
order to select the filtration method which would retain the highest number of 
viable mononuclear cells with the least particulate and unwanted matter, 2-ply 
sterile gauze, 100µm cell strainer and density centrifugation gradient were 
compared. The 2-ply sterile gauze gave a mononuclear cell loss of 18%, 
compared to 52% with the100µm cell strainer whilst density centrifugation 
gradient resulted in 87% cell loss. Thus, the gauze was selected as the optimal 





























Figure 4.1 Comparison of 3 filtration methods. Three filtration methods were 
compared to determine the method which allowed the least cell loss, while 
effectively removing unwanted debris. The T cell number in the induced 
sputum sample was calculated before and after filtration.  
 
 
In order to pellet the mononuclear cells to be plated in the ELISPOT wells, the 
sample was centrifuged at 1200rpm for 10 minutes, at which speed the viability 
of the induced sputum mononuclear cells was preserved. The optimal number of 
cells per well was determined as that which produced the highest number of 
ESAT-6-specific spot-forming cells (SFCs) per well with the same volume of 
antigen. The highest number of spots was seen when the induced sputum 








































































Figure 4.2A       Figure 4.2B 
 
Figure 4.2 Determination of optimal number of cells/well. ESAT-6-specific spot-
forming cells from 3 samples of induced sputum were plated in duplicate at 5 
increasing concentrations. The mean number of SFCs is shown (4.2A) and then 
reflected as a summated trendline of all 3 patients (4.2B). 
 
Validation phase 
The validation phase was carried out using the methods established in the 
optimisation phase. Seventy three of these subjects were included. 5/73 (7%) of 
individuals could not expectorate and sputum induction was prematurely 
terminated. Two patients experienced nausea and/or vomiting, while 3 suffered 
chest pain. Thus 68 TB suspects were enrolled in the validation phase of the 
study. 59 of the 68 (86.8%) assays failed (Table 4.3). 
 
In the 8 samples where the induced sputum volume (less salivary content) was 
insufficient for further processing, the nebulization time or sample volume 
appeared adequate in the nebulization booth. There was no correlation between 































































































induced sputum volumes, cell concentrations or age, and HIV status. A further 7 
samples could not be used as adequate filtration was prevented due to large 
mucus plugs disallowing homogenization. After successful homogenization, the 
samples were filtered and washed twice with phosphate buffered saline (PBS). 
The median (range) sputum cell concentration (cells/millilitre sputum) was 0.1 x 
106 cells/ml (0-2.4 x 106).  
 
The average mononuclear cell viability which was checked prior to plating was 
greater than 90%. Calculation of the total sputum cell numbers yielded highly 
variable values. In 24 individuals there were insufficient cells to perform the T-
SPOT®.TB assay which was the most common cause of assay failure. In 19 
cases the samples’ total cell yields were insufficient to plate the optimal 250 000 
cells/well. Consequently, these assays could be performed using concentrations 
above 100 000 cells/well. Differential cell counts were performed using the 
Wright stain on slides prepared after a cytospin. The differential cell counts 
showed a median (range) lymphocyte count of 21% (0-75%) and neutrophil count 
of 79% (10-95%).  
 
Twenty eight samples could be plated in the T-SPOT®.TB assay. However, of 
these 14 assays the positive or negative control well did not fulfil the 
manufacturer’s requirements i.e. clear positive well, or SFCs visible in the 
negative control well. In 6 samples, the background debris in the wells was too 


















Figure 4.3 Photographs showing ELISPOT results using mononuclear cells from 
induced sputum. PHA-driven IFN-γ-specific spot-forming cells using mononuclear 
cells from induced sputum are shown in Panel (A). A negative control well is 
shown in (B). (C) shows ESAT-6-specific spot-forming cells in a patient with TB. 
(D) shows an inconclusive result due to high background discoloration. (E) and 
(F) show artifacts due to non-specific debris and mucus. 
 
Therefore, despite optimisation of the assay to process the induced sputum only 
8 (11.8%) of the 68 assays included in the validation phase produced an 
evaluable result (Table 4.2). Seven assays were positive with a median (IQR) of 
96 (21,164) SFUs/106cells for the ESAT-6 and 64 (0,250) CFP-10 wells, 
respectively. All 7 positive samples were from TB patients and the single 
negative sample was from a non-TB patient. In 3 of the assays, wells with CFP-
10 antigen could not be plated due to an insufficient number of mononuclear cells 
isolated from the induced sputum sample. The reasons for failure of sputum 



















result Final diagnosis 
Spot forming units/106cells SI smear/culture 
ESAT-6 CFP-10 Positive control* 
Negative 
control* AFB smear 
MGIT 
culture 
        
positive Definite TB 120 not done# 100 40 positive positive 
positive Definite TB 176 not done# 64 40 positive positive 
positive Definite TB 160 not done# 80 20 positive positive 
positive Definite TB 28 >250 >250 0 negative positive 
positive  Definite TB+ 0 >250 >250 0 negative negative 
positive  Definite TB+ >250 0 60 0 negative negative 
positive  Probable TB 72 64 >250 12 negative negative 
negative Non TB 0 0 40 0 not done$ not done$ 
        
Median  96 64 90 0  
IQR  21/164 0/250 63/250 0/25  
 
*As per the manufacturer’s guidelines, an assay was considered valid if the number of 
SFU’s/106cells in the negative control well was twice that of the positive control well. A value of 
>250SFU’s/106cells was selected as the cut-off positive value.  
#Insufficient cells to plate both wells. 
+ Patients were found to be culture positive on other biological samples and therefore classified as 
definite TB. 





















Table 4.3 T-SPOT®.TB assay outcomes and reasons for inconclusive test results 
in the validation phase. 
 
*The Non-TB group included 1) 29 TB suspects classified as non-TB after follow-up and 2) non-
TB control patients with alternative respiratory diseases e.g. interstitial lung disease. 
+1 sample was rejected due to laboratory error 
Validation phase  (n=68)+ 
Test outcomes/reasons for test failures 




Sputum induction-related factors (n=39)   
1. Inadequate volume of sputum  1 7 
2. Failure to homogenise sputum 1 6 
3. Insufficient cells 6 18 
T-SPOT®.TB related factors (n=20)    
1. Excessive debris (high background) 1 5 
2. Positive control well failed 1 10 
3. Negative control well failed 2 1 
Valid T-SPOT®.TB result (n=8)    
1. Positive 7 0 













Patients who are either smear negative and sputum-scarce pose a diagnostic 
problem as diagnosis of TB is often made by identification of AFB in sputum. A 
disadvantage of this test is the number of false negative results obtained due to 
the need for a minimum of 5 000-10 000 bacilli/ml of sputum (Teixeira et al., 
2007). However, recent studies show that the yield of sputum induction 
compares well to bronchoscopy (Anderson et al., 1995; McWilliams et al., 2002). 
Sputum induction is far less invasive, requires less medical expertise, and is less 
costly making it a feasible option for primary clinics where the first possible 
contact for diagnosis of TB takes place.  
 
In this study, sputum induction was performed using a method based on that first 
described by Pin et al. to examine inflammatory cells in the airways (Pin et al., 
1992). A single specimen of induced sputum can be used for immunological 
(IGRA) and bacterial or histological (stain/culture) diagnosis of M.tb. While the 
volume of induced sputum produced in this study ranged between 4-12ml, a 
study by Brown et al. in 2007 showed that positive culture results are not 
dependent upon sputum volume (Brown et al., 2007). Similarly, the number of 
mononuclear cells isolated from the induced sputum samples in our study did not 
correlate with volume. Therefore, neither obtaining a larger sample volume, nor 
exposing the patient to sputum induction for longer, was likely to overcome the 
problem of insufficient cells which occurred in approximately 36% of our assays. 
Cell viability was greater than 90% in all samples analysed which compared 
favourably with 83% (SD=15.6%) reported by Pizzichini et al. (Pizzichini et al., 













Insufficient cell yield was the most common reason for unevaluable assays 
[34/68(50%)]. This is not surprising as sputum induction samples the large 
airways rather than the alveolar spaces where the majority of mononuclear cells 
reside.  The low cellular yield is exacerbated by the variable though low 
proportion of lymphocytes in pulmonary samples. Nevertheless, increasing the 
numbers of cells per well is unlikely to have increased the number of evaluable 
assays as demonstrated by the cell-cytokine response curves. 
 
Contamination with particulate debris and salivary squamous epithelial cells 
poses a problem when processing sputum, and has been approached using two 
alternative techniques. The entire expectorate, comprising sputum and variable 
amounts of saliva, can be processed as described by Fahy et al. (Fahy et al., 
1993). This method has subsequently been modified whereby saliva and sputum 
are collected separately (Gershman et al., 1996). Alternatively, the expectorate 
can be poured into a Petri dish and the more opaque, viscid sputum selected 
using an inverted microscope (Pavord et al., 1997). The former technique was 
selected in this study as it is far more feasible, quicker, and doesn’t require an 
inverted microscope which is often unavailable in resource-poor settings. 
However, there remains conflicting data as to whether or not the differential cell 
counts differ between the two techniques (Efthimiadis et al., 2002). This would be 
an important factor in determining assay reproducibility. 
 
Filtration further minimizes contamination of the samples. While 48μm nylon 
mesh was used by Pizzichini et al., this study showed 2-ply sterile gauze to be 
optimal (Pizzichini et al., 1996). In fact, the suspension of induced sputum 
homogenized with 0.1% DTT would not flow through the 48μm nylon mesh. Any 
remaining, contaminating squamous cells would only reduce the total and 
absolute cell counts of the induced sputum sample, but should not significantly 
alter the differential cell count. (The latter only becomes a consideration in 











ECP and IL-8 do seem to be adversely affected by squamous contamination, to 
date this effect on IFN-γ remains unconfirmed (Simpson et al., 2004).  
 
Of the 20 T-SPOT®.TB assays which were plated but unevaluable, 3 of the 
negative control wells failed i.e. had more than 6 SFCs. A study by (Martinez-
Maza et al., 1984; Quiding et al., 1993; Robinson et al., 1985) suggests this may 
be unavoidable. They showed that blood mononuclear cells may release a high 
degree of spontaneous IFN-γ in the absence of any exogenous stimuli. Although 
the positive control well failed in 11 of the 20 assays, the optimisation findings 
demonstrated that 250 000 cells/well was optimal and thus the concentrations of 
cells was not altered during the validation experiments. 
 
In contrast to these findings, Breen et al. demonstrated that induced sputum 
could successfully be used for immunological diagnosis of TB in 9 patients using 
PPD-driven cells in a flow cytometric or ELISPOT assay (Breen et al., 2007). 
However, the use of PPD to stimulate induced sputum mononuclear cells results 
in non-specific responses even in suspects with latent TB infection (LTBI). By 
contrast, RD-1 specific responses in the lung, as used in this study, are highly 
specific even in high burden countries where the prevalence of LTBI is over 50% 
(Dheda et al., 2009; Jafari et al., 2009). In addition, the ELISPOT assay requires 
far less training than flow cytometry, and is less costly making it more suitable for 
use in resource-poor settings. Breen et al. reported a total cell yield almost 6 
times greater than those found in our study. However, we used unselected and 
consecutively recruited patients, a different population group, and different 
sputum processing methodology. Several other factors including disease extent, 
the small number of patients evaluated by ELISPOT in the Breen study, the 
duration of sputum induction and volume of hypertonic saline used, and 
malnutrition and hence attenuated immune responses, may explain the 












Eight of the RD-1 ELISPOT assays in this study were evaluable (in seven the 
diagnosis was TB). The immunological and clinical diagnoses of the positive and 
probable TB patients were concordant. Of the 20 positive TB patients in the 
validation phase, 7 (35%) were positively diagnosed by the T-SPOT®.TB assay. 
This low sensitivity would prevent this IGRA using induced sputum mononuclear 
cells from being clinically useful, if used in isolation, to diagnose TB. 
 
In order to improve the ELISPOT utility, specific variables such as different 
media, culture of induced sputum mononuclear cells before plating in the wells, 
or variations in the concentration of capture-antibody in the wells, may be altered. 
As this small study was conducted in a high burden, resource poor setting, the 
findings require confirmation in different geographical settings with larger cohorts 
of patients. 
 
In conclusion, despite the low frequency of valid results, it was confirmed in this 
study that rapid immunodiagnosis of pulmonary TB by antigen-specific IFN-γ 
ELISPOT responses, using mononuclear cells from induced sputum, is indeed 
possible (Cashmore et al.). However, due to several technical factors the 
proportion of inconclusive results is too high to warrant current clinically utility. 
Pizzichini et al. showed that the induced sputum non-cellular fraction, after 
isolation of the cellular components, could be used to measure molecular 
markers indicative of airway inflammation such as eosinophil activation and mast 
cell activation (Pizzichini et al., 1996). Recent studies have shown that an 
antigen-detection ELISA assay using the non-cellular fraction of biological fluids 
can be successful for the diagnosis of TB (Boehme et al., 2005; Dheda et al., 
2009; Patel et al., 2009). Consequently, I proceeded to study the possibility of 
detecting LAM in the non-cellular fraction of induced sputum as a diagnostic 













FEASIBILITY OF A LAM ANTIGEN-CAPTURE ELISA ASSAY USING 
INDUCED SPUTUM TO DIAGNOSE TUBERCULOSIS 
 
INTRODUCTION 
Current diagnostic tools for tuberculosis are inadequate resulting in increased 
healthcare costs, higher patient mortality or morbidity, and greater long-term 
disability. TB diagnosis is particularly difficult in HIV-positive patients where 
smear microscopy is negative in 24-61% of pulmonary TB cases (Getahun et al., 
2007) and radiological and clinical features are often atypical (Burman and 
Jones, 2003; Getahun et al. 2010). Mycobacterial culture takes several weeks for 
positive results (Pai et al., 2006). Newer T-cell assays cannot be used as reliable 
rule-in tests for active TB diagnosis (Dheda et al., 2009), and molecular assays 
are not widely available in resource-poor, high-burden settings (Pai et al., 2006). 
Thus, reliable, affordable, rapid point f care (POC) diagnostic tests using non-
invasive, easily obtainable clinical specimens which are not influenced by the 
host’s level of immunosuppression are urgently needed (Pai et al., 2009; Urdea 
et al., 2006). 
 
More recently assays detecting secreted or circulating mycobacterial antigens, 
such as LAM, have been developed. LAM is an antigenic marker of the genus 
Mycobacterium and features amongst the candidate antigens for diagnostic TB 
serology. In order to measure the amount of LAM representative of 
M.tuberculosis infection, a LAM ELISA-based assay has been developed. This 
technique was first explored in sera (Sada et al., 1990). Many studies 
investigating the diagnostic performance of LAM in urine have been done. The 
LAM ELISA has also shown promise with the use of cerebrospinal fluid (Patel et 











developed an in-house capture ELISA to detect sputum LAM (Pereira Arias-
Bouda et al., 2000) and Dheda et al. tested the feasibility of using expectorated 
sputum in a LAM ELISA commercial assay (Dheda et al., 2010; van Zyl-Smit et 
al., 2009). The assay’s poor performance was attributed to cross-reactivity 







Figure 5.1 LAM positivity (>zero OD units=positive for LAM after subtraction of 
the negative control ie. Cutpoint is zero) in cultures of oral mouth flora and in 
organism-specific cultures (various Actinobacteria, including different strains of 
Nocardia and Streptomyces, and C.albicans, T.paurometabolum, and 
C.neoformans inoculated into normal broth culture [containing yeast extract] and 
Todd-Hewitt culture media [without yeast extract]. Normal oral flora from 6 













LAM-like molecules are not specific to mycobacteria as they are also found in 
actinomycetes (including the genera Rhodococcus, Corynebacterium or 
Gordonia), bacteria which are typical of mouth flora. Therefore, I hypothesized 
that an induced sputum sample would yield far better results as the mouth flora 
would be minimized or eliminated. 
 
Due to the potential advantages of using induced sputum as a biological sample 
for rapid and user-friendly diagnosis, this study aimed to evaluate the feasibility 












MATERIALS & METHODS 
 
Human subjects & sample processing 
 
A substudy involving 79 of the 101 TB suspects recruited for the ELISPOT assay 
was undertaken. Please refer to Chapter 2 for further details regarding collection 
and processing of induced sputum samples. 
 
Briefly, the induced sputum sample was homogenized, filtered, then centrifuged 
to isolate mononuclear cells. This non-cellular fraction was drawn off then heated 
and centrifuged. The suspension was evaluated for LAM content using the 
Clearview® TB ELISA  assay. The samples were evaluated as per the 
manufacturer’s instructions. 
 
Assays were normalised for volume, total number of cells, and protein content as 
the initial volume of sputum varied. Each normalisation strategy was compared. 
 
Statistical Analysis 
Performance of the LAM assay to correctly diagnose tuberculosis was compared 
to the reference standard (culture positivity). The appropriate parametric and non 
parametric tests were performed with GraphPad Prism version 4.00 (or higher) 
for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com. Additional tests were performed using OpenEpi, Version 2, 

















Seventy nine TB suspects were included in the study.  When stratified into the 4 
pre-defined subgroups, there were 12 individuals with definite TB, 14 with 
probable TB and 43 with non-TB. 10 individuals remained indeterminate and 
were thus excluded from the study. The mean (SD) age was 47 years (17 years). 
30% (21/69) of the cohort were HIV-positive (Table 5.1). In the definite TB group 
33% (4/12) were HIV positive compared to 16% (7/43) in the non TB group 
(p=0.23).  
 
Table 5.1 Demographic information of the TB suspects recruited for the study 
 Total Definite TB Probable TB Non-TB P 
Number of subjects 69* 12 14 43  
      
Age mean (SD) 47 (17) 41 (16)+ 44 (14) 50 (17)+ P=0.09 
      
Sex      
     Male 32 (46%) 8 (67%)+ 6 (43%) 18 (42%)+ P=0.15 
      
Race      
     Black African 27 (39%) 6 (50%)+ 8 (57%) 13 (30%)+ P=0.23 
     Mixed Ancestry 40 (58%) 6 (50%) 6 (43%) 28 (65%)  
     European Ancestry 2 (3%) 0 0 2 (5%)  
      
HIV status      
     Positive 21 (30%) 4 (33%)+ 10 (71%) 7 (16%)+ P=0.23 
     Unknown 11 (16%) 0 2 (14%) 9 (21%)  
      
Previous TB (n=54)      
     Yes 19/54 (35%) 4/8 (50%)+ 8/11 (72%) 7/35 (20%)+ P=0.12 











The Clearview® ELISA assay was used to calculate the LAM concentration 
(ng/ml) in the induced sputum samples. There was no statistically significant 
difference in the LAM concentrations (median, IQR) between the definite TB 
(0.66ng/ml, 0.12-3.21ng/ml) and the non-TB groups (0.13ng/ml, 0.0-1.14ng/ml) 
P=0.14. When combining the definite and probable TB groups no difference in 
LAM concentration was detected (P=0.59) (Figure 5.2) 
 
 


























Figure 5.2 Induced sputum LAM concentrations in the 4 pre-defined diagnostic 
subgroups. LAM concentration in ng/ml and horizontal line depicts median 
values. Def TB = Definite TB, Prob TB = Probable TB 
 
Normalising LAM concentrations for volume, protein concentration and cell count.  
As the LAM-containing supernatants were isolated from various volumes of 
induced sputum (range: 4-12ml), the LAM concentrations were normalised for 
original volume of sputum obtained. There was no significant difference between 











8.32ng) compared to the non-TB group (0.90ng; 0.0-4.0ng) (P=0.62). There was 



























Figure 5.3 Induced sputum LAM concentrations (ng/ml) normalised for original 
sputum volume (ml) LAM content in ng, horizontal lines depict median values. 
Def TB = Definite TB, Prob TB = Probable TB 
 
Similarly, the LAM concentration was normalised for protein content of the 
induced sputum. There was no significant difference when comparing the non-TB 
group with neither the definite TB group (P=0.19) nor with the combined definite 
& probable TB group (P=0.68), despite the median concentration of the definite 
TB group [0.78ng/mg (IQR: 0.17-4.33ng/mg)] being more than double that of the 


















































Figure 5.4 Induced sputum LAM concentrations (ng/ml) normalised for protein 
concentration (mg/ml) LAM content in ng/mg protein, horizontal lines depict 
median values. Def TB = Definite TB, Prob TB = Probable TB, 
 
 
Similarly no significant difference in LAM content between the pre-defined 
subgroups could be found when the LAM concentration was normalised for total 
number of cells. (Figure 5.5). There are 7 individuals in the Definite TB subgroup 
with zero LAM content, and 10 individuals in the Non-TB subgroup with a positive 
LAM content. This could be due to the indirect relationship between the cell-free 
fraction in which the LAM was measured and the number of induced sputum 











































Figure 5.5 Induced sputum LAM concentrations (ng/ml) normalised for total 
number of cells. LAM content in ng per cell. Def TB = Definite TB, Prob TB = 
Probable TB, 
 
Diagnostic performance of the induced sputum LAM  
Using the manufacturer’s pre-defined cut-point for LAM positivity (specifically 
defined for urine samples) in the definite TB group, the sensitivity of the LAM 
assay was 66.67% (95%CI 39.06-86.19%) and specificity was 53.49% (95%CI 
38.92-67.49%). Combining the definite and probable TB groups, the sensitivity 
decreased to 46.15% (95%CI 28.76-64.54%), while the specificity remained 
unchanged (Table 5.2). The effect of using a ROC-defined cut-point is discussed 
later. 
 
The assay performed worse in the HIV-positive compared to the HIV-negative 











57.14% (95%CI 25.05-84.18%) compared to the HIV-negative category [44.44% 
(95%CI 27.59-62.69%)] (Table 5.2).  
Characteristics of the test results are depicted in Figure 5.6. 
 
Table 5.2 The performance characteristics of LAM as a diagnostic test in the 
overall study population and subdivided into HIV positive and HIV negative 
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Figure 5.6 LAM interpretation of the overall study cohort.  










69* 43 26 Total  
37 23 14 negative 








   
21* 7 14 Total  
15 4 11 negative 








   
37* 27 10 Total  
14 12 2 negative 









 Total cohort 











Determining a ROC-derived LAM cut point 
LAM results were analysed using a receiver operating characteristic (ROC) curve 
to assess the global performance. This suggested that manipulation of the assay 

















Figure 5.7 ROC curves showing definite TB and combined definite & probable 
TB groups.  
 
Definite & Probable TB







































Table 5.3 ROC curve table for Definite TB subgroup 
Definite TB      
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.009047 43.75 19.75% to 70.12% 76.60 61.97% to 87.70% 1.87 
< 0.01955 43.75 19.75% to 70.12% 74.47 59.65% to 86.06% 1.71 
< 0.0430 43.75 19.75% to 70.12% 72.34 57.36% to 84.38% 1.58 
< 0.0675 43.75 19.75% to 70.12% 70.21 55.11% to 82.66% 1.47 
< 0.0800 43.75 19.75% to 70.12% 68.09 52.88% to 80.91% 1.37 
< 0.0935 43.75 19.75% to 70.12% 65.96 50.69% to 79.14% 1.29 
< 0.0980 43.75 19.75% to 70.12% 63.83 48.52% to 77.33% 1.21 
< 0.1085 43.75 19.75% to 70.12% 61.70 46.38% to 75.49% 1.14 
< 0.1235 43.75 19.75% to 70.12% 59.57 44.27% to 73.63% 1.08 
< 0.1300 43.75 19.75% to 70.12% 57.45 42.18% to 71.74% 1.03 
< 0.1401 43.75 19.75% to 70.12% 55.32 40.12% to 69.83% 0.98 
< 0.1648 43.75 19.75% to 70.12% 53.19 38.08% to 67.89% 0.93 
< 0.1852 43.75 19.75% to 70.12% 51.06 36.06% to 65.92% 0.89 
< 0.1915 43.75 19.75% to 70.12% 48.94 34.08% to 63.94% 0.86 
< 0.1945 43.75 19.75% to 70.12% 46.81 32.11% to 61.92% 0.82 
< 0.2035 43.75 19.75% to 70.12% 44.68 30.17% to 59.88% 0.79 
< 0.2185 43.75 19.75% to 70.12% 42.55 28.26% to 57.82% 0.76 
< 0.2275 43.75 19.75% to 70.12% 40.43 26.37% to 55.73% 0.73 
< 0.2386 43.75 19.75% to 70.12% 38.30 24.51% to 53.62% 0.71 
< 0.2701 50.00 24.65% to 75.35% 38.30 24.51% to 53.62% 0.81 
< 0.3115 50.00 24.65% to 75.35% 36.17 22.67% to 51.48% 0.78 
< 0.3412 50.00 24.65% to 75.35% 34.04 20.86% to 49.31% 0.76 
< 0.4083 56.25 29.88% to 80.25% 34.04 20.86% to 49.31% 0.85 
< 0.4895 56.25 29.88% to 80.25% 31.91 19.09% to 47.12% 0.83 
< 0.5271 56.25 29.88% to 80.25% 29.79 17.34% to 44.89% 0.80 
< 0.6645 62.50 35.43% to 84.80% 29.79 17.34% to 44.89% 0.89 
< 0.8879 68.75 41.34% to 88.98% 29.79 17.34% to 44.89% 0.98 
< 0.9958 68.75 41.34% to 88.98% 27.66 15.62% to 42.64% 0.95 
< 1.012 75.00 47.62% to 92.73% 27.66 15.62% to 42.64% 1.04 
< 1.155 75.00 47.62% to 92.73% 25.53 13.94% to 40.35% 1.01 
< 1.304 75.00 47.62% to 92.73% 23.40 12.30% to 38.03% 0.98 
< 1.350 81.25 54.35% to 95.95% 23.40 12.30% to 38.03% 1.06 
< 1.436 81.25 54.35% to 95.95% 21.28 10.70% to 35.66% 1.03 
< 1.604 81.25 54.35% to 95.95% 19.15 9.149% to 33.26% 1.00 
< 1.750 81.25 54.35% to 95.95% 17.02 7.647% to 30.81% 0.98 
< 1.830 81.25 54.35% to 95.95% 14.89 6.204% to 28.31% 0.95 
< 2.492 81.25 54.35% to 95.95% 12.77 4.832% to 25.74% 0.93 
< 3.125 81.25 54.35% to 95.95% 10.64 3.546% to 23.10% 0.91 
< 3.281 81.25 54.35% to 95.95% 8.511 2.368% to 20.38% 0.89 
< 4.259 81.25 54.35% to 95.95% 6.383 1.336% to 17.54% 0.87 
< 5.329 87.50 61.65% to 98.45% 6.383 1.336% to 17.54% 0.93 
< 5.726 87.50 61.65% to 98.45% 4.255 0.5196% to 14.54% 0.91 
< 7.584 93.75 69.77% to 99.84% 4.255 0.5196% to 14.54% 0.98 
< 10.01 100.0 79.41% to 100.0% 4.255 0.5196% to 14.54% 1.04 














Table 5.4 ROC curve table for Definite & Probable TB subgroup. 
Definite & Probable TB     
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.009047 48.00 27.80% to 68.69% 76.60 61.97% to 87.70% 2.05 
< 0.01955 48.00 27.80% to 68.69% 74.47 59.65% to 86.06% 1.88 
< 0.02402 48.00 27.80% to 68.69% 72.34 57.36% to 84.38% 1.74 
< 0.04602 52.00 31.31% to 72.20% 72.34 57.36% to 84.38% 1.88 
< 0.0675 52.00 31.31% to 72.20% 70.21 55.11% to 82.66% 1.75 
< 0.07765 52.00 31.31% to 72.20% 68.09 52.88% to 80.91% 1.63 
< 0.08765 56.00 34.93% to 75.60% 68.09 52.88% to 80.91% 1.75 
< 0.0935 56.00 34.93% to 75.60% 65.96 50.69% to 79.14% 1.65 
< 0.0980 56.00 34.93% to 75.60% 63.83 48.52% to 77.33% 1.55 
< 0.1085 56.00 34.93% to 75.60% 61.70 46.38% to 75.49% 1.46 
< 0.1235 56.00 34.93% to 75.60% 59.57 44.27% to 73.63% 1.39 
< 0.1300 56.00 34.93% to 75.60% 57.45 42.18% to 71.74% 1.32 
< 0.1401 56.00 34.93% to 75.60% 55.32 40.12% to 69.83% 1.25 
< 0.1648 56.00 34.93% to 75.60% 53.19 38.08% to 67.89% 1.20 
< 0.1852 56.00 34.93% to 75.60% 51.06 36.06% to 65.92% 1.14 
< 0.1915 56.00 34.93% to 75.60% 48.94 34.08% to 63.94% 1.10 
< 0.1945 56.00 34.93% to 75.60% 46.81 32.11% to 61.92% 1.05 
< 0.2035 56.00 34.93% to 75.60% 44.68 30.17% to 59.88% 1.01 
< 0.2185 56.00 34.93% to 75.60% 42.55 28.26% to 57.82% 0.97 
< 0.2275 56.00 34.93% to 75.60% 40.43 26.37% to 55.73% 0.94 
< 0.2386 56.00 34.93% to 75.60% 38.30 24.51% to 53.62% 0.91 
< 0.2701 60.00 38.67% to 78.87% 38.30 24.51% to 53.62% 0.97 
< 0.3115 60.00 38.67% to 78.87% 36.17 22.67% to 51.48% 0.94 
< 0.3412 60.00 38.67% to 78.87% 34.04 20.86% to 49.31% 0.91 
< 0.4083 64.00 42.52% to 82.03% 34.04 20.86% to 49.31% 0.97 
< 0.4895 64.00 42.52% to 82.03% 31.91 19.09% to 47.12% 0.94 
< 0.5271 64.00 42.52% to 82.03% 29.79 17.34% to 44.89% 0.91 
< 0.6100 68.00 46.50% to 85.05% 29.79 17.34% to 44.89% 0.97 
< 0.7343 72.00 50.61% to 87.93% 29.79 17.34% to 44.89% 1.03 
< 0.8015 76.00 54.87% to 90.64% 29.79 17.34% to 44.89% 1.08 
< 0.9006 80.00 59.30% to 93.17% 29.79 17.34% to 44.89% 1.14 
< 0.9958 80.00 59.30% to 93.17% 27.66 15.62% to 42.64% 1.11 
< 1.012 84.00 63.92% to 95.46% 27.66 15.62% to 42.64% 1.16 
< 1.155 84.00 63.92% to 95.46% 25.53 13.94% to 40.35% 1.13 
< 1.304 84.00 63.92% to 95.46% 23.40 12.30% to 38.03% 1.10 
< 1.350 88.00 68.78% to 97.45% 23.40 12.30% to 38.03% 1.15 
< 1.436 88.00 68.78% to 97.45% 21.28 10.70% to 35.66% 1.12 
< 1.604 88.00 68.78% to 97.45% 19.15 9.149% to 33.26% 1.09 
< 1.750 88.00 68.78% to 97.45% 17.02 7.647% to 30.81% 1.06 
< 1.830 88.00 68.78% to 97.45% 14.89 6.204% to 28.31% 1.03 
< 2.492 88.00 68.78% to 97.45% 12.77 4.832% to 25.74% 1.01 
< 3.125 88.00 68.78% to 97.45% 10.64 3.546% to 23.10% 0.98 
< 3.281 88.00 68.78% to 97.45% 8.511 2.368% to 20.38% 0.96 
< 4.259 88.00 68.78% to 97.45% 6.383 1.336% to 17.54% 0.94 
< 5.329 92.00 73.97% to 99.02% 6.383 1.336% to 17.54% 0.98 
< 5.726 92.00 73.97% to 99.02% 4.255 0.5196% to 14.54% 0.96 
< 7.584 96.00 79.65% to 99.90% 4.255 0.5196% to 14.54% 1.00 
< 10.01 100.0 86.28% to 100.0% 4.255 0.5196% to 14.54% 1.04 













A simple, rapid, low cost POC diagnostic test is urgently needed, especially in 
smear-negative patients and in TB-high burden countries where the prevalence 
of HIV-co-infection can be as high as 80% (Corbett et al., 2003). Induced sputum 
appears to be ideal as it is non-invasive, relatively easy to obtain, offers a yield 
equal to that of bronchoscopy and is patient-friendly. Similarly, antigen-detection 
ELISA assays may be advantageous as they are able to directly detect bacterial 
replication, potentially enabling them to differentiate active infection from latent 
TB and to reflect disease stage and/or treatment progression. In addition, these 
assays do not rely on optimal host immunological functioning.  
 
The performance of LAM in induced sputum using the Clearview® ELISA assay 
was disappointing. Despite correcting for several factors, the diagnostic 
performance could not be improved upon.  In the overall cohort, the sensitivity 
was 66.67% (95%CI 39.06-86.19%) with a specificity of 53.49% (95%CI 38.92-
67.49%). In the combined definite and probable TB group, the sensitivity 
decreased to 46.15% (95%CI 28.76-64.54%), while the specificity remained 
unchanged (Table 5.2). The reason for these results could be attributed to the 
sputum quality as sensitivity and specificity are affected by this. Sputum induction 
samples the larger airways, so samples may be susceptible to contamination by 
environmental lung contaminants such as air pollution and cigarette smoke. 
Furthermore, mucins contain charged, glycosylated proteins which could cross-
react with the glycosylated proteins making up mycobacterial LAM (Mall et al., 
1999). This may explain the high LAM levels in the non-TB patients. As these 
glycosylated proteins could adhere to each other, the filtration step may remove 
LAM caught in the mucus globules, thereby decreasing assay sensitivity. 
However, more likely the polyclonal antibodies fail to recognise the LAM 











antibodies. We performed a heating step to try and dissociate LAM from antibody 
in such complexes. The efficacy of this heating step is unclear. 
 
Interestingly, the test is marketed for use in HIV-positive patients (as per the 
manufacturer’s instructions), so one could expect its performance to improve in 
the HIV-positive subgroup. However, HIV is a paucibacillary disease which could 
explain the low sensitivity of 25% (95%CI 4.55-69.94%) in the TB-HIV-co-
infected subgroup versus the improved sensitivity of 87.5% (95%CI 52.91-
97.76%) in the HIV-negative individuals. The sputa of HIV-positive patients have 
a low burden of M.tb compared to the tissues. A question exists whether patient 
TB-burden may impact on LAM concentration. In disseminated HIV-disease with 
advanced immunosuppression, sputum LAM concentration may be relatively low 
despite a high-TB burden elsewhere in the body e.g. high urine LAM as it is 
filtered through the kidneys. This hypothesis is confirmed by Mutetwa et al. who 
reported that test sensitivity in urine was higher in HIV-positive (52%) patients 
than in HIV-negative (21%) individuals (Mutetwa et al., 2009). Dheda et al. 
showed similar findings where LAM in urine was associated with HIV-positivity 
and test sensitivity was significantly higher in the HIV-positive population 
compared to uninfected individuals (21% versus 6%; p< 0.001) (Dheda et 
al.,2010). A later study of LAM in urine reported a sensitivity of 50.5% and 
specificity of 78.3% (Tessema et al., 2002). It was hypothesized that their assay’s 
poor performance could have been attributed to patient HIV-status, latent TB, 
intravascular LAM-anti-LAM complex formation, or environmental mycobacterial 
infections, such as M.leprae, or M.avium.  
 
Dheda et al.’s most recent study examined expectorated sputum and reported 
sensitivity and specificity to be 86% and 15% respectively. Dheda attributes the 
low specificity found in expectorated sputum to cross-contamination of 
mycobacterial LAM antigen in the cell walls of mouth flora and mouth 











reported by LM Pereira Arias-Bouda et al. who reported 91% sensitivity using 
expectorated sputum in an in-house LAM capture ELISA assay (Pereira Arias-
Bouda et al., 2000). Induced sputum, as used in my study, showed poor 
specificity yet better than the studies using expectorated sputum. This may be 
due to less contamination with mouth flora as the technique of sputum induction 
samples secretions from the lower airways. Nevertheless, one must 
acknowledge that some contamination during expectoration is unavoidable.  
 
The sensitivity measured in induced sputum in this study has been shown to be 
less than in expectorated sputum (Dheda et al., 2010). This may partly be due to 
laboratory processing methods. The homogenization and digestion of mucins 
and debris could lead to the destruction of target antigens. The induced sputum 
was filtered through 2-ply sterile gauze and centrifuged before the non-cellular 
fraction was drawn off and heated as part of the defined protocol described in the 
previous chapter. In comparison, Dheda et al. placed the spontaneous sputum 
directly into the heated waterbath (Dheda et al., 2010). It is uncertain how this 
may have affected the final LAM concentrations. As already mentioned, LAM and 
immunoglobulins may form LAM-anti-LAM complexes thereby decreasing the 
available LAM to bind to the assay antibodies (Tessema et al., 2002).  
 
These poor results may, in part, be due to the use of an alternative body, fluid i.e. 
induced sputum, as the Clearview® ELISA assay was commercially designed for 
use with urine. Consideration would need to be made of differing sputum 
characteristics, compared with urine, such as viscosity and pH. A further practical 
difficulty in this project was the blurring of clinical and radiographic features of 
pulmonary TB (PTB) by host immunosuppression, especially in HIV-positive 
patients. This made it especially difficult to categorize patients hence we used 












This study is the first to evaluate the use of induced sputum in the Clearview® 
LAM ELISA kit. The sensitivity, specificity, and positive and negative predictive 
values are too low to warrant clinical utility. It was conducted in a TB-high 
burden, resource-poor population therefore a larger study in a different 
geographical setting is needed to verify the results.  
 
In future, adjustments to the existing Clearview® LAM ELISA assay for specific 
use with induced sputum may perhaps improve its efficacy. Reagents designed 
specifically for use with sputum and/or induced sputum may improve 
performance. This could necessitate the initial design of in-house assay, such as 
that of Chan et al. (2000). Additionally, use of ethanol precipitation, which has 
been used to concentrate antigens from bacterial cultures, may result in LAM 
being more detectable. Further investigation is required to find alternative and 















CONCLUSION & FUTURE PROSPECTS 
 
Tuberculosis has become a public health catastrophe in the developing world. It 
is endemic in South Africa and is especially prevalent in the Western Cape, 
where the disease incidence in certain areas is above 1 500/100 000 per year 
(Wood et al., 2007). Current tools are suboptimal thus there is an urgent need for 
user friendly and accurate, rapid TB diagnostic tests.  
 
Most of the studies concerning interferon gamma release assays (IGRAs) done 
in high incidence areas appear to contradict the findings of those studies 
performed in low incidence settings. A meta-analysis performed by Dheda et al. 
involving studies done in high incidence settings, such as Uganda, The Gambia 
and India showed that IGRA sensitivity might be lower than in low incidence 
settings (Dheda et al., 2009). Although the TST is less specific in BCG-
vaccinated individuals, it is as sensitive as the IGRAs in active disease and 
concordance with the TST is modest to good. Any discordance is predominantly 
TST-positive, IGRA-negative as is the case in my study.  (Dheda et al., 2009). 
This may suggest variable T cell activity across populations depending on such 
immuno-modulatory factors as tuberculosis prevalence, malnutrition, HIV/AIDS, 
BCG vaccination, exposure to NTMs, leprosy, helminth and other such tropical 
infections.  
 
The tuberculin skin test (TST) has historically been the only diagnostic test for 
latent TB infection. There is a large amount of prospective data to validate the 
positive predictive value of the TST (Comstock, 1975). However, its efficacy may 
be compromised by many factors including patient immune status, reader bias 











Calmette-Guérin (BCG) vaccination. In addition, it is subject to the “booster” 
phenomenon so patients cannot be tested more than once within a short period 
of time. The IGRAs have been developed as a potential replacement or 
adjunctive, diagnostic test for LTBI. They show arguably better sensitivity and 
specificity than the TST yet there is a 10-40% discordance rate between the two 
tests (Pai et al., 2004). The reasons for this are unclear. 
 
In this thesis, TST-positive, IGRA-negative individuals showed an increased 
expression of biomarkers associated with regulatory T cells (Tregs) and 
immunosuppressive cytokines such as IL-4 in skin biopsy samples. Guyot-Revol 
et al. showed that ex vivo Tregs have an attenuating effect on peripheral blood 
IFN-γ-producing CD4-cells responsible for the Th1-immune response associated 
with active TB (Guyot-Revol et al., 2006). Such suppression of IFN-γ production 
by effector cells, may compromise the IGRA resulting in “false” negative tests. 
Thus, it could be beneficial to directly explore the effect of Tregs in the T-
SPOT®.TB assay by using peripheral blood mononuclear cells (PBMCs) with and 
without Tregs and then determining whether they affect the number of  spot-
forming cells (SFCs) obtained per well. Future work is required to address this 
question. 
 
While the TST is useful in detecting LTBI, the more recently developed IGRAs 
may be useful for the immunodiagnosis of active TB. If there is a high frequency 
of M.tb-specific T cells within a specific disease compartment, it may be possible 
to diagnose active TB. For example, T cell assays have been both diagnostically 
and clinically useful in diagnosing PTB when using BAL fluid (Dheda et al., 
2009). Similarly, I have shown that IGRAs can be successfully performed to 
diagnose TB using cells from induced sputum, although this assay is not clinically 
viable in it’s current format (Cashmore et al., 2010). The T-SPOT®.TB was tested 
in this thesis using an alternative biological fluid, namely induced sputum. 











comparable yield. In addition, a single induced sputum specimen can be used for 
immunological (IGRA), and microbiological diagnosis of M.tb. Sputum induction 
doesn’t require much medical expertise and is ideal for patients who are sputum-
scarce e.g. HIV, or unable to self-expectorate; therefore, I reasoned that it could 
potentially be an ideal technique for resource-poor areas. This study evaluated 
TB antigen-specific (ESAT-6 and CFP-10) enzyme-linked immunospot assay 
(ELISPOT) responses using mononuclear cells isolated from induced sputum 
samples. The results showed that very few (<12%) assays could be evaluated as 
there were insufficient mononuclear cells obtained from the sample to plate the 
required 250 000 lymphocytes/well for the T-SPOT®.TB kit. The efficiency of the 
assay could possibly be improved by changing assay-specific variables such as 
i) proliferation of induced sputum mononuclear cells before plating,  ii) depletion 
of immunosuppressive cells, e.g. Tregs, before the assay, iii) use of stimulatory 
antigens other than or in addition to ESAT-6 and CFP-10, iv) use of 
staphylococcal enterotoxin B (SEB), rather than PHA, as a positive control, or v) 
increase of the cut-off number of SFCs for negativity (It has been shown that 
airway pathogens activate BAL alveolar T cells possibly contributing to an 
increased spot count in the negative control (Dheda et al., 2009). Future work is 
required to address these issues. 
 
For the IGRA assay to diagnose active TB in sputum it may be possible to 
simultaneously investigate the response of a combination of cytokines, such as 
IL-2 and IFN-γ, in the same test to better understand the underlying cellular 
activities. It would also be especially helpful in highly TB endemic areas to 
identify and validate novel antigens or biomarkers, capable of discriminating LTBI 
from active TB or helpful in following effectiveness of treatment (Sargentini et al., 
2009). Demmissie et al. have reported that the 16-kDa Rv2031c antigen is 
largely restricted to latently infected individuals (Demissie et al., 2006). New 











protein-10 (IP-10) and monocyte chemotactic protein-2 (MCP-2) (Dheda et al., 
2009; Jafari and Lange, 2008; Ruhwald et al., 2007; Wilkinson et al., 2005) 
An alternative to cellular assays using induced sputum is the lipoarabinomannan 
(LAM), enzyme-linked immunosorbent assay (ELISA). However, the Clearview® 
TB LAM ELISA performed disappointingly as an indicator of M.tb infection with a 
sensitivity of only 66.67% and specificity of 53.49%. Mycobacterial LAM may be 
cross-reacting with LAM-like microbial surface molecules in the cell walls of 
mouth-residing mouth flora. Similarly, there may be cross-reactivity between 
mycobacterial LAM and mucins in induced sputum as both are made up of 
glycosylated proteins (Mall et al., 1999). Mucins can be extracted then purified by 
caesium chloride density gradient ultracentrifigation. LAM could possibly then be 
isolated by gel filtration, SDS-PAGE and Western blotting of these isolated 
mucins (Mall et al., 1999). As the Clearview® TB ELISA assay was designed for 
use in urine, its usefulness using induced sputum could potentially be improved 
by alternative sputum-specific reagents.  
 
In conclusion, a rapid cost effective and ideally point of care test is urgently 
needed for the diagnosis of active TB. Unfortunately induced sputum ELISPOT 
and LAM testing do not appear to be promising candidates. In addition an 
accurate, cheap and reliable test for latent TB is also required. Although the 
IGRA assays hold great promise, understanding the reasons for TST-IGRA 
discordance may help drive the development of an improved test platform. The 
lack of a gold standard for LTBI however remains a major stumbling block in the 
development of any novel LTBI diagnostic assay. Finally it remains imperative to 
test any novel TB assay in both TB endemic areas and low burden settings as 
assay performance, cost and acceptability is not always comparable between 
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